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It has been shown that all forms of cardiomyopathy, including the dilated, hypertrophic, 
restrictive, and right ventricular arrhythmogenic forms, are found in African populations. 
Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a rare muscle disease 
characterised by fibrofatty replacement of the right ventricular myocardium, leading to 
electrical instability and eventual heart failure. Dilated cardiomyopathy (DCM) is a disease 
characterised by a reduction in ventricular wall thickness which leads to reduced 
contractility and impaired ventricular function. Mutations that cause ARVC have been 
reported in five desmosomal and three non-desmosomal genes.  Among the desmosomal 
genes is desmoplakin (DSP) which encodes the desmoplakin protein. DSP has previously 
been shown to cause ARVC and DCM. We hypothesise that mutations in DSP may be 
causative of ARVC and familial and idiopathic DCM in our cohort of South African patients  
We recruited consecutive probands with ARVC and fDCM from Grootte Schuur Hospital in 
Cape Town.  Informed consent was obtained from 62 well characterised ARVC and 150 well 
characterised DCM (19 familial, 131 idiopathic) probands. Probands were screened for 
mutations in DSP by means of high resolution melt analysis and DNA sequencing. Population 
screens were conducted on novel variants to determine the frequency of variants in the 
South African control population. 
The frequency of disease-causing mutations in DSP was 3% in cases of ARVC (2/62 
probands), 5% in cases of familial DCM (1/19 probands) and 4% in apparently sporadic cases 
of DCM (5/131 probands). We also detected a number of variants of unknown significance 
which will require further study to determine their role in disease pathogenesis. We found 
mutations that were common to both the ARVC and DCM cohorts, and were determined to 
be causative of both these diseases. 
We have shown that mutations in DSP are causative of ARVC and DCM in South African 
cohorts. We have demonstrated that a large number of familial dilated cardiomyopathy 
probands harbour mutations in the DSP gene. We have also shown that the same mutations 
can cause ARVC and DCM, which suggests that ARVC and DCM may form part of a common 
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1.1. STRUCTURE AND FUNCTION OF THE HEART 
The heart is responsible for the circulation of blood throughout the body. The heart has four 
chambers, namely the right and left atria which receive blood from the venous system, and 
the right and left ventricles which pump blood into the arterial system (Figure 1.1). The right 
atrium is separated from the left atrium by the muscular wall known as the inter-atrial 
septum; similarly the right ventricle and left ventricle are divided by the interventricular 
septum. Valves of the heart include the tricuspid valve (which separates the right atrium 
and ventricle), the mitral valve (which separates the left atrium and ventricle), the 
pulmonary valve (which separates the right ventricle from the pulmonary artery) and the 
aortic valve (which separates the left ventricle from the aorta) (Fox 2006). 
Deoxygenated blood enters the right atrium of the heart through the superior and inferior 
vena cava and then goes to the right ventricle, which subsequently pumps the blood 
through the pulmonary artery to the lungs where it is oxygenated. The oxygenated blood 
then travels to the left atrium of the heart via the pulmonary veins, and then to the left 
ventricle, from where it is pumped through the aorta to the entire body (Fox 2006). 
 
Figure 1.1: Structure of the heart (©Mayo Foundation for Medical Education and Research) 
(Electronic Resource 1) 
                     Deoxygenated blood flow 
                     Oxygenated blood flow 
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The walls of the cardiac chambers are composed of three layers: the epicardium, the 
myocardium and the endocardium. These layers are surrounded by the pericardium (Figure 
1.2). The cells of the myocardium are called cardiomyocytes and are specialised muscle cells 
that are striated, as they contain actin and myosin filaments arranged in the form of 
sarcomeres, which allow the contraction of the cardiomyocytes. These cells are short, 
branched and interconnected by different types of intercellular junctions (Fox 2006). The 
main functions of the myocardium are the generation of contractile forces (by the 











Figure 1.2: Layers of the heart (©Mayo Foundation for Medical Education and Research) 
(Electronic Resource 2) 
1.2. CARDIOVASCULAR DISEASE 
Cardiovascular disease (CVD) is the leading cause of death in all developing countries with 
the exception of sub-Saharan Africa (Opie and Mayosi 2005, Gaziano 2007) and is the 
second largest cause of mortality (after HIV/AIDS) in South Africa (Bradshaw et al. 2003). 
CVD has an enormous social and economic impact on society, causing great suffering and 
loss of life as well as posing major economic challenges to developing countries, including 
costs to the healthcare systems and to the national economy (Gaziano 2005, Gaziano 2007).  
CVD can be attributed to many causes, including hypertension, high cholesterol, tobacco 
and alcohol use and low fruit and vegetable consumption (Gaziano 2005). The major 
causative factors in Africa, however, are hypertension, rheumatic heart disease and 
cardiomyopathy (Sliwa et al. 2005).  Cardiomyopathy poses the greatest challenge of the 
cardiovascular disease causative factors in Africa because of its prevalence in societies that 
are still plagued by famine and pestilence and do not have access to proper resources or 
effective interventions, besides the difficulty of diagnosis and the high mortality associated 




Cardiomyopathy is defined as a myocardial disease in which the heart muscle is structurally 
and functionally abnormal, without hypertension, coronary artery disease, valvular disease 
or congenital heart disease which is sufficient to cause the observed myocardial abnormality 
(Elliot et al. 2008). Cardiomyopathies often lead to progressive heart failure with significant 
morbidity and mortality, and can be primary (genetic, mixed or acquired) or secondary 
(infiltrative, toxic or inflammatory) (Wexler et al. 2009). Cardiomyopathies are classified into 
morphological and functional phenotypes, which are then subclassified into familial and 
non-familial forms (Elliot et al. 2008). Types of cardiomyopathy include dilated 
cardiomyopathy (DCM), restrictive cardiomyopathy (RCM), hypertrophic cardiomyopathy 
(HCM), arrhythmogenic right ventricular cardiomyopathy (ARVC) and unclassified 
cardiomyopathies (Elliot et al. 2008). This study will focus primarily on ARVC and DCM. 
1.3.1. Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) 
ARVC is a rare inherited muscle disease that predominantly affects the right ventricle and is 
an important cause of sudden death in people aged ≤35 years (Sen-Chowdhry et al. 2010). It 
is characterised by the replacement of cardiomyocytes by fibrofatty tissue, primarily in the 
right ventricle (Figure 1.3), which leads to electrical instability including ventricular 
arrhythmias in the early stages and later reduced contractility and heart failure (Awad et al. 
2008, Kiès et al. 2006). Recently, other subtypes of this disease with left ventricular 
involvement have been recognised, namely left-dominant and biventricular types of 
arrhythmogenic cardiomyopathy (Sen-Chowdhry et al. 2010). 
 
 




The initial phase of the disease is known as the concealed phase and involves a 
predisposition to ventricular arrhythmia and sudden cardiac death whilst having well-
preserved morphology, histology and ventricular function (Sen-Chowdhry et al. 2010). As 
the disease progresses, the myocardial disorder becomes more evident. Myocyte loss 
occurs, which may be accompanied by fat infiltration, fibrosis and inflammation (Sen-
Chowdhry et al. 2010). Fibrofatty replacement of the right ventricular myocardium is 
progressive, and starts from the epicardium or the mid myocardium and eventually leads to 
wall thinning and aneurysms (Basso et al. 2009). Fibrofatty replacement interferes with the 
conduction of electrical impulses which causes the epsilon waves, right bundle branch block, 
late potentials and ventricular arrhythmias seen in individuals with ARVC (Basso et al. 2009). 
Other structural abnormalities that occur in this disease include increased trabeculation, 
global ventricular dilation and dysfunction and clinical heart failure, though this only occurs 
in some individuals at late stages of the disease (Sen-Chowdhry et al. 2010). Ventricular 
arrhythmias are worse during or immediately after exercise, and participation in 
competitive exercise has been associated with an increased risk of sudden death. 
ARVC is estimated to have a prevalence ranging from 1 in 1000 to 1 in 5000 and accounts for 
up to 10% of deaths from undiagnosed cardiac disease in people aged <65 years (Sen-
Chowdhry et al. 2010, Basso et al. 2009). ARVC affects more men than women (in a ratio of 
3:1) and usually presents within the second to fourth decade of life (Corrado et al. 2009, 
Basso et al. 2009). 
Patients who are suspected to have ARVC must undergo clinical assessments which include 
evaluation of symptoms and family history, physical examination, chest radiograph, 12-lead 
ECG, 24-hour ambulatory ECG, signal-averaged ECG, stress test and two-dimensional 
echocardiography. Further assessments include cardiac magnetic resonance imaging, 
contrast angiography and endomyocardial biopsy (Basso et al. 2009). The clinical diagnosis 
of ARVC is often difficult due to the non-specific nature of the disease features and the 
broad spectrum of physical manifestation (Corrado et al. 2009).  
The diagnosis of ARVC is based on the presence of criteria that include structural, 
histological, electrocardiographic, arrhythmic and genetic factors that are characteristic of 
the disease (McKenna et al. 1994) (Table 1.1). These criteria are divided into major and 
minor criteria, based on their specificity for ARVC. An initial set of task force criteria was 
presented in 1994 by McKenna and colleagues, and a revision of these criteria has recently 
been proposed by Marcus and colleagues (Marcus et al. 2010). The 1994 task force criteria 
were used for the diagnosis of ARVC in this project. 
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Table 1.1: Task Force Criteria for the Diagnosis of ARVC (McKenna et al. 1994) 
 
 
A familial background has been demonstrated in at least 50% of cases and the disease is 
typically transmitted as an autosomal dominant trait (Corrado et al. 2009, Basso et al. 2009). 
The penetrance of ARVC is reduced and frequently age-dependent, while affected relatives 
often have variable and incomplete disease expression (Sen-Chowdhry et al. 2010). 
 
CRITERIA DESCRIPTION 
Global and/or regional 
dysfunction and structural 
alterations 
MAJOR 
Severe dilatation and reduction of right ventricular ejection 
fraction with no (or only mild) left ventricular impairment 
Localised right ventricular aneurysms (akinetic or dyskinetic areas 
with diastolic bulging) 
Severe segmental dilatation of the right ventricle 
 
MINOR 
Mild global right ventricular dilatation and/or ejection fraction 
reduction with normal left ventricle 
Mild segmental dilatation of the right ventricle 
Regional right ventricular hypokinesia 
Tissue characterization of 
walls 
MAJOR 
Fibrofatty replacement of myocardium on endomyocardial biopsy 
Repolarization abnormalities MINOR 
Inverted T waves in right precordial leads (V2 and V3) (people aged 




Epsilon waves or localised prolongation (> 110 ms) of the QRS 
complex in right precordial leads (V1-V3) 
 
MINOR 
Late potentials (signal averaged ECG) 
Arrhythmias MINOR 
Left bundle branch block type ventricular tachycardia (sustained 
and non-sustained) (ECG, Holter, exercise testing) 
Frequent ventricular extrasystoles (more than 1000/24 h) (Holter) 
Family history MAJOR 
Familial disease confirmed at necropsy or surgery 
 
MINOR 
Familial history of premature sudden death (<35 yrs) due to 
suspected right ventricular dysplasia 
Familial history (clinical diagnosis based on present criteria) 
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1.3.2. Dilated Cardiomyopathy (DCM) 
DCM is a common form of the cardiomyopathy that is characterised by dilated cardiac 
chambers and reduced left ventricular systolic function (Moolman-Smook 2003, Hughes et 
al. 2005; Luk et al. 2009) (Figure 1.4). Symptoms and signs include dyspnoea, fatigue, 












Figure 1.4: Comparison of the dilated cardiomyopathy heart and the normal heart (©Mayo 
Foundation for Medical Education and Research) (Electronic Resource 4) 
In South Africa and Uganda, DCM accounts for 10-17% of all cardiac conditions which are 
found at autopsy, while in many other parts of Africa, DCM accounts for 17-48% of patients 
who are hospitalised for heart failure (Sliwa et al. 2005). The incidence of DCM in the United 
States and elsewhere has been reported to be 4-8/100 000 person-years, while the 
prevalence of this disease is reported to be 36.5/100 000 individuals (Sliwa et al. 2005). 
However, there is no population-based data on the burden of this disease in Africa as yet. 
The diagnosis of DCM is confirmed by non-invasive cardiac imaging, particularly with two-
dimensional echocardiography (Schönberger and Seidman, 2001). Diagnosis is made by the 
exclusion of any underlying cardiac diseases such as coronary artery disease, valvular heart 
disease and arterial hypertension (Fourlas et al. 2004). 
Patients may present with the disease during childhood, but most patients present in the 
fourth or fifth decade of life (Schönberger and Seidman, 2001). Modes of inheritance of the 
familial form of this disease include autosomal dominant, autosomal recessive and X-linked 
inheritance (Luk et al. 2009). Autosomal dominant forms of DCM are caused by mutations in 
cytoskeletal, sarcomeric protein/Z-band, nuclear membrane and intercalated disc protein 
genes. The X-linked form of DCM is associated with diseases such as muscular dystrophies 
(Elliot et al. 2008). The disease may also occur in patients with mitochondrial cytopathies 
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and inherited metabolic disorders. Disease progression and severity varies, as family 
members with identical mutations may show variable penetrance (Luk et al. 2009). Although 
25-35% of patients have a genetically inherited (familial) form of DCM, the majority of 
individuals with this disease have an acquired form which may be caused by nutritional 
deficiencies, endocrine dysfunction and the administration of cardiotoxic drugs (Elliot et al. 
2008). 
1.3.3. Molecular Genetics of ARVC and DCM 
ARVC is caused by mutations in desmosomal protein genes in up to 50% of symptomatic 
individuals (Awad et al. 2008), whereas the causes of DCM are largely unknown, although 
several genes have been implicated in this disorder (Burkett et al. 2005). To date, 12 
different chromosomal loci have been associated with ARVC (Table 1.2) (Awad et al. 2008). 
Eight genes have been identified at these loci, five of which encode desmosomal proteins. 
The fact that the genes encoding the desmosomal components have been implicated in 
ARVC suggests that ARVC is essentially a disease of the desmosome. The first desmosomal 
gene mutation found to be associated with ARVC was a mutation in the JUP gene which 
encodes the plakoglobin protein (McKoy et al. 2000).  This mutation was found in patients 
with Naxos disease, which is characterised by ARVC, palmoplantar keratoderma and woolly 
hair (McKoy et al. 2000, Corrado et al. 2006, Awad et al. 2008). The genes encoding the 
desmoplakin (DSP), plakophilin (PKP2), desmoglein (DSG2) and desmocollin (DSC2) 
desmosomal proteins have also been implicated in ARVC, with PKP2 being the main 
contributor to the genetic causes of ARVC, representing 11-43% of ARVC causative 
mutations (Fowler et al. 2010). 
Table 1.2: Chromosomal Loci and Disease-causing Genes in ARVC (From Awad et al. 2008) 
DESIGNATION LOCUS SYMBOL DISEASE GENE 
ARVD1 14q23-q24 TGFβ3 Transforming Growth Factor- β3 
ARVD2 1q42-q43 RyR2 Cardiac Ryanodine Receptor 
ARVD3 14q12-q22 ? Unknown 
ARVD4 2q32.1-q32.3 ? Unknown 
ARVD5 3p23 TMEM43 Transmembrane protein 43 
ARVD6 10p12-p14 ? Unknown 
ARVD7 10q22 ? Unknown 
ARVD8 6p24 DSP Desmoplakin 
ARVD9 12p11 PKP2 Plakophilin 2 
ARVD10 18q12.1- q12.2 DSG2 Desmoglein 2 
ARVD11 18q12.1 DSC2 Desmocollin 2 
ARVD12 / Naxos 17q21 JUP Plakoglobin 
 
However, three non-desmosomal genes have also been implicated in this disease. These 
include RyR2 (which encodes the ryanodine receptor) (Tiso et al. 2001), TGFβ3 (which 
encodes transforming growth factor β3 (Beffagna et al. 2005) and TMEM43 (which encodes 
the transmembrane protein 43) (Merner et al. 2008). A summary of the genes involved in 




Table 1.3: Summary of Desmosomal and Non-Desmosomal Genes Implicated in ARVC and the 
prevalence of mutations in these genes (from Sen-Chowdhry et al. 2007, Fowler et al. 2010) 
GENE (SYMBOL) LOCUS ESTIMATED PREVALENCE (%) 
Plakoglobin (JUP) 17q21 <1 
Desmoplakin (DSP) 6p24 1-20 
Plakophilin (PKP2) 12p11 11-43 
Desmoglein (DSG2) 18q12-q12.2 12-40 
Desmocollin (DSC2) 18q12 ~1.5% 
Transforming Growth factor beta 3 (TGFβ3) 14q24 <1 
Cardiac Ryanodine Receptor (RyR2) 1q42.1–q43 <1 
Transmembrane protein 43 (TMEM43) 3p25.1 <1 
 
At least 25 different chromosomal loci have been associated with familial DCM (Table 1.4). 
Genes encoding proteins that have cytoskeletal, contractile and calcium regulatory 
functions have been discovered at these loci, reflecting the genetic heterogeneity of the 
disease (Ahmad et al. 2005). Additional phenotypes such as skeletal myopathy have also 
been discovered in conjunction with DCM in patients with various gene mutations. 
Table 1.4: Chromosomal Loci and Disease-causing Genes in DCM (From Ahmad et al. 2005) 
LOCUS SYMBOL DISEASE GENE ADDITIONAL PHENOTYPE 
1p1–q21 LMNA Lamin A/C Conduction disease, skeletal myopathy 
1q32 TNNT2 Cardiac troponin T2 None 
2q14–q22 ? Unknown Conduction disease 
2q31 TTN Titin None 
2q35 DES Desmin Skeletal myopathy 
3p22–p25 ? Unknown Conduction disease 
5q33 SGCD Delta sarcoglycan Skeletal myopathy 
6p23–p24 DSP Desmoplakin Woolly hair, keratoderma 
 6q12–q16 ? Unknown None 
6q22.1 PLN Phospholamban None 
6q23–q24 ? EYA4 Skeletal myopathy, sensorineural hearing loss 
9q13–q22 ? Unknown None 
9q22–q31 ? Unknown None 
10q22–q23 MVCL Metavinculin Mitral valve prolapse 
10q22.3–q23.2 LDB3 Cypher/ZASP Left ventricular noncompaction 
11p11.2 MYBPC3 Cardiac myosin binding protein C None 
11p15.1 CLP Cardiac muscle LIM protein None 
12p12.1 ABCC9 ATP-sensitive K channel Arrhythmias 
14q12 MYH7 Beta myosin heavy chain None 
15q14 ACTC Cardiac actin None 
15q22 TPM1 Alpha tropomyosin None 
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LOCUS SYMBOL DISEASE GENE ADDITIONAL PHENOTYPE 
16p11 CTF1 Cardiotrophin 1 None 
19q13.2 ? Unknown Conduction disease 
Xp21 DMD Dystrophin Skeletal myopathy 
Xq28 TAZ Tafazzin Skeletal myopathy 
 
1.4. DESMOSOMES 
Desmosomes are specialised intercellular junctions that anchor intermediate filaments to 
the cytoplasmic membranes in adjacent cells, thus forming a supportive network. They play 
a key role in imparting mechanical strength via cell-cell adhesion and transmission of force 
between the junctional complex and the intermediate filaments in the cytoskeleton (Sen-
Chowdhry et al. 2007). Desmosomes are found most abundantly in regions that undergo a 
high amount of mechanical stress, such as the heart and the skin (Sen-Chowdhry et al. 2007, 
Stokes 2007). 
Desmosomes are similar to adherens junctions and hemi-desmosomes in structure, the 
difference being that these junctional complexes have different protein components (Stokes 
2007). The principal sites of adhesion are in the extracellular domains of transmembrane 
proteins which belong to the cadherin family, that are characterised by five tandem 
extracellular domains (Stokes 2007). The cadherins which form part of the desmosomal 
complex are desmocollin-2 (DSC2) and desmoglein-2 (DSG2) (Sen-Chowdhry et al. 2007). 
The intracellular portion of the desmosome consists of a plaque which can be divided into 
the outer dense plaque (which is closer to the cell membrane) and the inner dense plaque 
(which is located further away from the cell membrane) (Figure 1.5). The outer dense 
plaque consists of the intracellular portions of the cadherin proteins as well as members of 
the armadillo protein family, namely junctional plakoglobin (JUP) and plakophilin-2 (PKP2). 
The inner dense plaque consists of desmoplakin (DSP) which connects the desmosomal 




Figure 1.5: Structure of the desmosome (from Sen-Chowdhry et al. 2007) 
ODP – Outer Dense Plaque; IDP – Inner Dense Plaque; DSP – Desmoplakin; JUP – Junctional 
Plakoglobin; PKP-2 – Plakophilin-2; DSC-2 – Desmocollin-2; DSG-2 – Desmoglein-2 
Mutations which alter the structure and function of the desmosome could lead to myocyte 
detachment and death and subsequent fibrofatty tissue infiltration (Sen-Chowdhry et al. 
2007, Awad et al. 2008). However, mutations in responsible genes demonstrate incomplete 
penetrance and variable expressivity, suggesting that genetic modifiers and environmental 
factors play a role in the etiology of these disorders (Awad et al. 2008). 
In this study, the focus is on the DSP gene which encodes the desmoplakin protein. This 
gene accounts for 1-20% of ARVC mutations (Marcus et al. 2007, den Haan et al 2009, Fowler et 
al. 2010, Fressart et al. 2010) and has also been implicated in a syndromic form of DCM, 
known as Carvajal syndrome, which is characterised by DCM, woolly hair and palmoplantar 
keratoderma (Norgett et al. 2000). Therefore, the DSP gene is a good candidate for 
investigations of the genetic aetiology of familial and apparently idiopathic forms of DCM. 
 
1.5. DESMOPLAKIN 
1.5.1. Organisation of the DSP gene 
The DSP gene is located on the short arm of chromosome 6, in the region 6p24.3 (Lai 
Cheong et al. 2005) and has orthologues in a number of species including chimpanzee (Pan 
troglodytes), dog (Canis familiaris), gorilla (Gorilla gorilla), mouse (Mus musculus) and rat 
(Rattus norvegicus). It is 45077 base pairs (bp) in length and has 24 exons, the last two of 
which are particularly large in comparison to the others (Figure 1.6). These exons (exon 23 




1.5.2. The desmoplakin protein 
Desmoplakin is one of the largest desmosomal plaque proteins. The desmoplakin protein is 
expressed in two isoforms, namely DSPI and DSPII, which are 2871 and 2272 aa in length 
respectively (Bolling et al. 2010). The DSP protein has three domains: the N-terminus, the 
rod domain and the C-terminus (Yang et al. 2006) (Table 1.5). The N-terminus and the C-
terminus are globular domains and they have the central rod domain between them (Lai 
Cheong et al. 2005). The desmoplakin N-terminus contains six α-helical bundles named NN, 
Z, X, Y, W and V while the C-terminus contains A, B and C repeat domains that are important 
for the interaction of desmoplakin with intermediate filaments (Figure 1.7) (Lai Cheong et al. 
2005). 
Table 1.5: Domains of the DSP protein and their functions 
DOMAIN SIZE FUNCTION REFERENCE 
N-terminus 1056 aa 
-  Localisation of desmoplakin to the desmosome 
- Interaction of desmoplakin with plakoglobin 
and plakophilin 
Yang et al. 2006 
Rod domain 889 aa (DSPI) or 290 aa (DSPII) Homodimerisation of the desmoplakin protein Stokes 2007 
C-terminus 926 aa 
Interaction of desmoplakin with the intermediate 
filaments in the cell 
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Figure 1.7: Schematic representation of the domains of desmoplakin and their subdivisions 
(from Lai Cheong et al. 2005)  
The desmoplakin protein is known to form a homodimer (Lai Cheong et al. 2005). The 
difference in length of the DSPI and DSPII proteins is due to DSPII having a shortened rod 
domain compared to DSPI (290 vs 889 aa). DSPI is 322 kD in size while DSPII is 259 kD in size 
(Lai Cheong et al. 2005). 
Both the DSPI and DSPII isoforms are expressed abundantly in the skin, but while DSPI is 
expressed abundantly throughout the heart, DSPII is only expressed in certain areas of the 
heart (left atrium and ventricle, interventricular septum, left auricular appendage and apex 
of the heart and at much lower levels than DSPI) (Uzumcu et al. 2006). Desmoplakin is also 
found outside desmosomes, in cellular junctions between endothelial cells which line 
capillaries (Gallicano et al. 1998) and is important for the formation of blood vessels in vitro 
(Zhou et al. 2004). Desmoplakin is important in the stabilisation of desmosomes and the 
establishment of tissue development, as demonstrated by the fact that Dsp null mice die in 
embryogenesis (Gallicano et al. 1998, Lai Cheong et al 2005). 
1.5.3. DSP mutations 
To date, a number of mutations have been described in the DSP gene in patients with ARVC 
(Basso et al. 2006, Bauce et al 2005, Rampazzo et al. 2002, Yang et al. 2006) and syndromic 
DCM associated with woolly hair and palmar plantar keratosis (Norgett et al. 2000). These 
mutations include splice site mutations, nonsense mutations, missense mutations, 
insertions, deletions and duplications (van der Zwaag et al. 2009). An ARVC database has 
been established which lists all mutations that have been found in patients with ARVC to 
date (http://www.arvcdatabase.info/) (van der Zwaag et al. 2009). This list of mutations 
includes published and unpublished mutations. Most disease-causing mutations have been 
identified in exons 23 and 24; exon 23 encodes part of the rod domain, while exon 24 
encodes part of the rod domain and the entire C-terminus. A detailed list of the pathogenic 
DSP mutations which have been previously discovered follows in Table 1.6 (from: 
http://www.arvcdatabase.info/). 
Desmoplakin has also been implicated in a number of other diseases including lethal 
acantholytic epidermolysis bullosa (Jonkman et al. 2005), keratosis palmoplantaris striata 
(Armstrong et al. 1999) and skin fragility-woolly hair syndrome (Whittock et al. 2002). 
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1.6. MECHANISMS OF DISEASE 
Several mechanisms have been proposed to explain the link between desmosomal gene 
mutations and ARVC. One mechanism is the degeneration-inflammation model of 
desmosomal dysfunction. In this model, desmosomal mutations that result in desmosomal 
dysfunction could impair cell-cell adhesion or intermediate filament function or both, 
depending on the effect of the mutation on protein structure and function (Sen-Chowdhry 
et al. 2010). The tissue would then have reduced ability to withstand mechanical stress, 
which would lead to cellular detachment and necrosis. This may be accompanied by 
inflammation. When the regenerative capacity of the myocardium is exceeded, the 
myocytes are instead replaced with fibrous and/or fatty tissue (Sen-Chowdhry et al. 2010, 
Awad et al. 2008). 
Another disease model is the transdifferentiation model. This model involves the Wnt/β-
catenin signalling pathway which has been implicated in the regulation of cell fate, 
proliferation and apoptosis. Usually, the Wnt/β-catenin signalling pathway promotes gene 
expression which causes the cell to differentiate into a cardiomyocyte and suppresses the 
expression of genes that promote adipogenesis and fibrogenesis. Plakoglobin, also known as 
γ-catenin, is structurally and functionally similar to β-catenin. In the event of a mutation that 
affects the localisation of plakoglobin (e.g., a mutation that suppresses the expression of 
desmoplakin), plakoglobin translocates to the nucleus where it can function in a similar 
manner to β-catenin and cause upregulation of adipogenic and fibrogenic genes (Sen-
Chowdhry et al. 2010, Awad et al. 2008). 
Recent studies have shown evidence of gap junction remodelling and aberrant calcium 
homeostasis in the presence of desmosomal gene mutations (Awad et al. 2008). It is not 
known which of these mechanisms are responsible for the phenotype of ARVC, or whether 
there is interplay between these mechanisms (Sen-Chowdhry et al. 2010). 
In Cape Town, a unique opportunity exists for the application of powerful molecular 
techniques for studies that could improve the understanding of the pathogenesis of ARVC 
and DCM. Groote Schuur Hospital in Cape Town has the only cardiac electrophysiology 
facility in the public sector in Africa and has been selected as the coordinating centre for the 
national registry of patients with ARVC in South Africa. The combination of unique patient 
resources and sophisticated molecular genetics laboratory at UCT makes it possible to 
propose a detailed study of the molecular genetics and relationships between genetic 
factors and the outcome in ARVC and DCM. We thus propose to extend the knowledge 
about the cardiomyopathy in the South African patients by screening ARVC and familial and 








Mutations in desmosomal genes may be associated with a phenotype that is characteristic 
of both ARVC and DCM (Kolar et al. 2008), as in the case of DSP gene mutations which have 
been associated with an ARVC or DCM phenotype with palmoplantar keratoderma (Lai 
Cheong et al. 2005, Norgett et al. 2000). The DSP gene is one of the important genetic 
causes of ARVC, accounting for 1-20% of mutations which are responsible for ARVC (Marcus 
et al. 2007, den Haan et al 2009, Fowler et al. 2010, Fressart et al. 2010). We hypothesise that 
mutations in DSP may be causative of ARVC and familial and idiopathic DCM in our cohort of 
South African patients. 
 
1.8. AIMS 
The aims of this study were to determine the prevalence of DSP mutations in a cohort of 
South African patients with ARVC, and to determine whether these mutations could be 
causative in familial and idiopathic DCM. By screening large numbers of affected individuals, 
we aimed to provide a definitive perspective on the contribution of DSP mutations to the 
aetiology of ARVC and DCM in South Africa. 
 
1.9. OBJECTIVES 
- To screen for DNA mutations within the DSP gene in probands with ARVC,  familial 
and idiopathic  DCM 
- To determine the prevalence of novel DSP mutations in controls drawn from the 
South African population 
- To screen the family members of the probands with novel DSP mutation that are not 
observed in the general population  
- To use in silico methods of predicting whether mutations that are not 





2. MATERIALS AND METHODS 
2.1. STUDY DESIGN 
This was a study of cases with ARVC, familial DCM and idiopathic DCM.  The ARVC cases were 
ascertained from the South African national registry for patients with ARVC which was 
established in 2003 (the ARVC Registry of South Africa) (Watkins et al. 2009).  The ARVC 
patients were referred to the ARVC Registry of South Africa by physicians from the major 
hospitals in Cape Town, Durban, Johannesburg, and Port Elizabeth. The cases of familial and 
idiopathic DCM were also referred to the Cardiomyopathy Clinic at Groote Schuur Hospital by 
physicians from all over the country. 
This project is part of ongoing studies of the genetics of cardiomyopathy that have been 
approved by the Research Ethics Committee of the University of Cape Town (REC REF 197/1996 
and 016/2002 (Khogali et al. 2001; Matolweni et al. 2006). 
2.2. PATIENT SELECTION 
ARVC cases  
Physicians refer suspected cases of ARVC and their first-degree relatives to the Coordinating 
Centre in the Cardiac Clinic, Groote Schuur Hospital, Cape Town, for consideration for 
enrolment in the registry. 
 
DCM cases 
The patients with DCM were referred to the Cardiomyopathy Clinic in the Cardiac Clinic of 
Groote Schuur Hospital for evaluation of cause and advice on management by Professor 
Bongani Mayosi. 
2.2.1. Diagnostic evaluation 
A standardised case report form is completed for all participants and available family members 
with ARVC, DCM and other cardiomyopathies.  Information on presenting symptoms, family 
history, electrocardiographic findings, cardiac imaging studies, histology, and outcome is 
collected. Participants are followed up annually to identify recurrent symptoms, hospitalisation, 
use of medications and implanted devices and vital status. Informed consent was obtained 
from all participants (Appendix 1). 
 
2.2.1.1. Inclusion criteria 
ARVC cases 
A diagnostic panel consisting of a group of cardiologists determined, by consensus, whether or 
not the referred cases met the diagnostic criteria for ARVC set by the Task Force of the Working 
Group on Myocardial and Pericardial Diseases of the European Society of Cardiology and of the 
Scientific Council on Cardiomyopathies of the International Society and Federation of 
Cardiology (McKenna et al. 1994). The participants were classified as having definite ARVC (if 
Task Force criteria were met), probable or possible ARVC (if some criteria were met and no 
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alternative diagnosis was found), or not having ARVC (if there was no evidence of ARVC and/or 
an alternative diagnosis was present). The diagnosis of ARVC in first-degree relatives of affected 




The diagnosis of DCM was made on the basis of the definition of the European Society of 
Cardiology (Elliott et al. 2008).  
2.2.1.2. Exclusion criteria 
Patients with secondary causes of cardiomyopathy or left ventricular dysfunction (such as 
hypertension, valvular heart disease, diabetes, coronary artery disease, or sepsis) were 
excluded from the study. 
2.3. CONTROL SELECTION 
Controls were chosen from a South African population comprising anonymous blood donors 
(self-reported ethnicity for these individuals was: Cape Mixed Ancestry, Black African, Indian 
and Caucasian). Informed consent was obtained from all participants. 
2.4. DNA ISOLATION AND STORAGE 
The DNA was extracted from 5-10ml blood using the PureGene
TM
 DNA Purification System 
(Gentra systems) according to the instructions of the manufacturer.  Written informed consent 
was obtained from all individuals enrolled in the study.  Extracted DNA samples were stored in 
1.5ml Eppendorf tubes at -80°C for longterm storage.  Individuals were given codes to 
anonymise the samples and ensure the confidentiality of the patients. 
2.5. MUTATION SCREENING OF DSP 
High Resolution Melt (HRM) analysis with the RotorGene 6000 (Corbett Life Sciences) was used 
for the mutation screening of DSP.   The predicted promoter region and the 5’ and 3’ 
untranslated regions of this gene as well as all the exons were amplified by polymerase chain 
reaction (PCR).   All amplicons showing changes with HRM were sequenced to determine the 
nature of the change.  
2.5.1. High Resolution Melt (HRM) Analysis 
Mutation detection by HRM analysis involves two steps: amplification of the DNA sequence of 
interest using PCR and analysis of the produced amplicon by HRM.  With the RotorGene 6000 
(Corbett Life Sciences), these two steps can be combined into a single procedure where DNA 





2.5.1.1. The principle of HRM Analysis 
HRM is used to characterise double stranded DNA according to its dissociation behaviour. This 
is accomplished by monitoring the transition from double stranded DNA to single stranded DNA 
with increasing temperature. It is used for the detection of mutations, polymorphisms and 
epigenetic differences between DNA samples. When compared to other methods for detecting 
these DNA alterations, HRM analysis has been proven to be more cost-effective, rapid, 
straightforward and powerful. 
HRM is the process of warming of the amplicon of DNA from ~50°C to ~95°C, or an alternative 
temperature range of choice. Before HRM analysis, the target sequence must be amplified to a 
high copy number. This is achieved by means of a DNA amplification reaction such as PCR in the 
presence of an intercalating dye. This dye does not interact with single stranded DNA and 
intercalates only with double stranded DNA, and when bound, fluoresces. This shift in 
fluorescence can be used to measure DNA concentration in a pre-HRM amplification, and can 
also be used to monitor the thermally-induced DNA dissociation by HRM. 
At the beginning of HRM there is a high level of fluorescence, due to the presence of billions of 
copies of the amplicon. At some point during HRM, the melting temperature of the two strands 
is reached and the DNA strands melt apart (Figure 2.1). As these strands melt apart, the amount 
of double stranded DNA in the solution decreases. Consequently, the fluorescence of the 
solution decreases. The RotorGene 6000 measures the fluorescence and plots the data as a 
melting curve that reflects the change in the fluorescence of the solution with the increasing 
temperature, as shown in Figure 2.2. The midpoint of the melting curve, where the rate of 
change in fluorescence is the greatest, is known as the melting temperature (Tm) of the 
particular DNA fragment under analysis. The melting temperature and melting behaviour of a 
DNA fragment is dependent on the DNA sequence, and thus sequence differences due to 
mutations would change the melting temperature and be reflected in the melting curve. 
 
 




Figure 2.9: Melt Curve for High Resolution Melt Analysis (HRM Assay Design and Analysis 
CorProtocol™ 6000-1-July06) 
However, as organisms possess two copies and thus two alleles of each gene, there are three 
genotype possibilities: firstly, that neither allele possesses a mutation (also known as wildtype), 
secondly, that one of the alleles possesses a mutation (known as a mutation heterozygote) and 
thirdly that both alleles possess a mutation (known as a mutation homozygote). These different 
cases are clearly distinguishable on the melt curve, as shown in Figure 2.3. In this way, 
homozygous and heterozygous mutations can be clearly distinguished from control samples by 
means of this technique. 
Figure  2.10: Melt curve indicating difference between homozygous and heterozygous samples 
(Electronic Resource 5) 
In this study, probands with ARVC and DCM were screened for mutations by comparing them to control 
samples known to be negative for the disease. 
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2.5.2. Polymerase Chain Reaction (PCR) 
DNA segments of interest are amplified by means of PCR prior to HRM in the presence of an 
intercalating dye. 
2.5.2.1. The principle of PCR 
PCR is a technique that allows the amplification of specific regions of DNA.  Two 
complementary oligonucleotide sequences which flank the target DNA segment, known as 
primers, direct the specific amplification of the desired DNA fragment, making use of Taq 
polymerase and deoxynucleotide triphosphates (dNTPs), under specific temperature cycling 
conditions.  The concentration of target DNA in the solution is essentially doubled with each 
cycle and ultimately generates multiple target sequence copies which are used in downstream 
applications (Garrett et al. 2005). 
In this project, sample DNA was amplified using real-time PCR, which allows the amplification 
and simultaneous quantification of a DNA sequence. This PCR is done in the presence of an 
intercalating dye that does not interact with single stranded DNA and intercalates with only 
double stranded DNA, and fluoresces when bound. The dye used for the pre-HRM PCR in this 
project is the EvaGreen dye. The increase in the amount of DNA in the solution as the PCR 
progresses causes a shift in the fluorescence of the solution, which can be used to measure 
DNA concentration at different times during the reaction. 
2.5.2.2. Primer design 
Primers were designed to amplify DSP, the 5’ and 3’ untranslated regions (UTRs) as well as the 
promoter region as predicted by Gene2Promoter (Electronic Resource 6). Primer sequences 
were chosen manually by (1) referring to the annotated DSP gene sequence, and (2) analysing 
the chosen sequences using IDT OligoAnanlyzer 
(http://www.idtdna.com/analyzer/Applications/OligoAnalyzer/Default.aspx) and NCBI BLAST 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi) web-based tools in order to determine the optimal 
primer sequences for the amplification of the gene.     
The primers were required to have: (1) good sequence diversity with minimal sequence repeats 
and secondary structure, (2) a length of between 18 and 25 base pairs, (3) a melting 
temperature of between 50°C and 60°C, (4) a GC content of between 45% and 65%, and (5) a G 
or C clamp at the 3’ end.  
The amplicon sequences were also restricted to a 250-300bp length due to the fact that with 
HRM, increased amplicon size leads to decreased resolution in amplicon screening and 
mutation detection.  Using these criteria, fifty sets of primers were designed for the combined 
PCR and HRM amplification and analysis of the 24 DSP exons, while 8 sets of primers were 






Table  2.7: Details of primers for the PCR and HRM of the 24 DSP exons 









1 F CTGAGCCGCTCTCCCGATTG 20 60.4 65.0 280 
R AGTCTCCCAGTCGTCCAG 18 56.0 61.1 
2 F GGGTAAAGGGTCTCACAGG 19 54.8 57.9 288 
R CTAACCAGAGGACAGTCGG 19 54.4 57.9 
3 F GTCATGTTTACAGTGGAAGC 20 51.4 45.0 336 
R AGGAAGCCCTGGGTCATG 18 57.2 61.1 
4 F CGGGTTTTCATAGGCTGTTTTC 22 54.5 45.5 286 
R CCATCGTGCTGGAACGTCTG 20 58.5 60.0 
5 F GTGATGGTGTGCGTAAGTG 19 53.8 52.6 285 
R AGAAACTCCCTGGGATTGAG 20 54.0 50.0 
6 F CTATGGAGGGATCTGAGGC 19 54.1 57.2 250 
R CCCGCCAGGATGTGCTTG 18 59.4 66.7 
7 F GCAGAGAACACCAGTCAC 18 53.1 55.6 303 
R CCAATCATTCCCCGAGAC 18 52.8 55.6 
8 F CTGTGGGGGTGATGGAAG 18 55.4 61.1 273 
R GTTGGCACGGCTTTAAGTC 19 54.4 52.6 
9 F GCAGGCTCACCTATCTCTTG 20 55.1 55.0 322 
R GCAAATCTATGCTACTCTGCACTC 24 55.7 45.8 
10 F GCCACCTGTCAAAGAGATG 19 52.6 53.4 316 
R CAGAGCCAACTGCATCCAAG 20 56.4 55.0 
11 F ATCTCCTCTAAAACTCACAGGG 22 53.7 45.5 329 
R CAAAGACATTGACTGTGGTG 20 51.6 45.0 
12 F CTTATGAATAAAGCCAAACCCTG 23 52.1 39.1 273 
R GGTATAAACACCTGCCCTC 19 52.6 52.6 
13 F AGTGGTGTGAGCGTGTCCAG 20 59.7 60.0 327 
R TTGACGAGACACAAAAGCAC 20 53.5 45.0 
14 F GATTGCATTGTGGGGCAGTC 20 57.0 55.0 382 
R TGCACGAAGAACACTGGC 18 55.9 55.6 
15 
F1 AGCCAGTGTTCTTCGTGC 18 55.6 55.6 227 
R1 CTATCTGCCTGCGAATCTTC 20 53.1 50.0 
F2 GAAACATGGATGCTGATGG 19 51.4 47.4 318 
R2 CCAGCCTGATAACCGTCTAC 20 54.8 55.0 
16 
F1 CCATGGAAGTTGACTGATGTG 21 52.0 48.0 305 
R1 GCCATCTGTAACACCATTG 19 51.3 47.4 
F2 GATATGCTTGCCAACTTCAG 20 51.6 45.0 256 
R2 CATGCTCTCCAAACCACAG 19 53.7 52.6 
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17 F AGCTGTGAGAGGCAAATCTTC 21 55.1 47.6 300 
R ATGAAAACCCAGTGAGGC 18 52.6 50.0 
18 F TGGTGACTTGTAGTGTAGC 19 51.5 47.4 317 
R GAACAACCAAAAGGGGAGAAG 21 53.9 47.6 
19 F CTGGGTGATTCTATGTTAC 19 47.2 42.1 318 
R GCACTGATACAAAAACCAG 19 49.1 42.1 
20 F TGCTCATCTCCTAAGCTG 18 51.2 50.0 346 
R TTGCTATCCTCAGGAAGTG 19 51.4 47.4 
21 F CTGTGGAACTGTAGCTGTTAG 21 52.8 47.6 311 
R TGGGATGAAATCAGCAATGG 20 53.1 45.0 
22 F GGCCCTTTGTTTTGCTGTAC 20 52.0 48.0 376 
R CAGTTTCACCAGGATGTGTC 20 52.0 50.0 
23 
F1 TGCACATTGGTCTGGGAG 18 55.0 55.6 356 
R1 CATAAGTCAGTCGGGTGATC 20 52.5 50.0 
F2 CTGAAGAGACAGGCTGAG 18 52.0 55.6 348 
R2 GTTTCTTACCTTTGCCAGCTC 21 54.1 47.6 
F3 TGAAAGGTTGAGGGTTCTAC 20 51.8 45.0 343 
R3 CATTATCTCAGAGCCACAGGC 21 55.4 52.4 
F4 AGCATCTTGCAGGCCACTG 19 58.4 57.9 261 
R4 TTCATATTCCCAGCGGCG 18 55.3 55.6 
F5 CACAAGCAGTCCCTGGAG 18 55.6 61.1 326 
R5 GTTAGAGTGTTCTTCAGCC 19 50.3 47.4 
F6 AGTGGCTACCGGGCTCAG 18 59.7 66.7 343 
R6 CATCTTCCAGGCATTTCCG 19 53.8 52.6 
F7 ATCTCTTGATGATGCTGCC 19 52.4 47.4 346 
R7 CCTCTTCAGCCGATTCAGC 19 55.9 57.9 
F8 TCCCAGGAGAGGACTGTG 18 55.8 61.1 289 
R8 CATCCAGCACGTCCCTCTG 19 58.0 63.2 
F9 GCTGAAGGAGCAAGCCATC 19 56.5 57.9 262 
F9 ATCTTCTATCGCCTTCTGG 19 51.2 47.4 
F10 CCAGGAACAGGAAAGTGTC 19 53.0 52.6 260 
R10 GCTGGCTCCTTAGTTCCAAG 20 55.6 55.0 
F11 GGAGTACGATGACCTGAG 18 51.5 55.6 278 
R11 GCAGAAAGAGCACAGTTC 18 51.2 50.0 
24 
F1 GCTCACAGTGTATCCAGGGAC 21 57.3 57.1 347 
R1 CTGTTTCTCACACTCCAGGC 20 55.7 55.0 
F2 GGAGGATGAGCTGAATCG 18 52.5 55.6 301 
R2 GCGTTCTGTTTCTAACTGTGAC 22 54.0 45.5 
F3 CGAAAGACTCCAAGCAGAG 19 53.0 52.6 346 
R3 ACCCCGAAGGAATGGCTG 18 57.7 61.1 
F4 CGACAAAACAACCTTGGAC 19 51.9 47.4 300 
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R4 ATCTGCTGACGGTCATCG 18 54.6 55.6 
F5 CATCGGAATGAGAAGCTGAC 20 53.5 50.0 264 
R5 CAAGGCGACATCTTTTGGC 19 54.8 52.6 
F6 TCAGGGGGTGTAGTAGAC 18 52.5 55.6 318 
R6 CAGTTCATTGACAGTGGACGG 21 55.9 52.4 
F7 TCCAAGGAATCAGACAACC 19 51.9 47.4 344 
R7 CTCAATGCCCACCAGACC 18 56.0 61.1 
F8 AAGCCCAAGCAGCTACTGG 19 57.8 57.9 293 
R8 GCTATGTCAACTGGTAAACG 20 51.2 45.0 
F9 CTTATTAGAAGCACAGATCGC 21 51.0 42.9 289 
R9 CCTGAGGGTATTCTTTTGTGATG 23 53.5 43.5 
F10 CAGGGCTCTGTCTTCTGC 18 55.6 61.1 314 
R10 GAACTTCCTGTCAACAAGGC 20 53.9 50.0 
F11 GGTGGTCCTGGTAGATAG 18 50.9 55.6 318 
R11 ATGGCTGCAATGGGGCTC 18 58.8 61.1 
F12 CACCATATCCAGCGTCAG 18 52.8 55.6 321 
R12 ACACCCTCGAAGCCTATGAAGG 22 58.7 54.5 
F13 CTGTCACTTCAGGACGCAGT 20 57.1 55.0 326 
R13 GGGCAGGTCAGGATTTTGG 19 56.3 57.9 
F14 GGAAGGGGTTCATAGATGGC 20 55.3 55.0 217 
R14 CCCGGAGCCGAAGACATG 18 58.5 66.7 
F15 TATCACTGGGCTGCGCCTTC 20 60.0 60.0 336 
R15 TGTCCTATCACTCTACTGC 19 50.5 47.4 
 
Table  2.8 : Details of primers for the PCR and HRM of the DSP predicted promoter region and 
the 5’ and 3’ UTR 










F1 AGGAAGTCGTGGTTTTCTG 19 52.4 47.4 301 
R1 TCGGGCTGGGAATGCGTG 18 61.1 66.7 
F2 TTCCAGCTATTTCCGCCC 18 55.1 55.6 319 
R2 CACCTGGCCGGTTTCTTC  18 56.4 61.1 
F3 CACCCTGGGAAGAAACCG  18 55.9 61.1 273 
R3 CAAGGATAGGCGGACGGC  18 58.5 66.7 
5'UTR F TCCGAGCCACAGCTTTCC 18 57.8 61.1 277 
R TCATGCGGCCCAGAGTGTTG 20 60.4 60 
3' UTR 
F1 GAGTGGTTGCTATACCTTG 19 50.1 47.4 216 
R1 CACTTCAGACGCACTGCATC 20 56.4 55.0 




R2 GAGTGTGGATTGTATAACCC 20 50.2 45.0 
F3 AGTCATTCTGCTTCTCATC 19 49.2 42.1 280 
R3 CATAAAGACACCTTAAAGTACATC 24 49.4 33.3 
F4 TGCATGACAGCGGCAATC  18 56.4 55.6 337 
R4 CATCGGGTACATGACAGG  18 52.4 55.6 
2.5.3. Combined PCR and HRM Protocol 
The reagents used for the combined real-time PCR and HRM of the DSP amplicons are shown in 
Table 2.3 and the reaction conditions are shown in Table 2.4. SensiMix HRM Kits (Quantace) 
were used for HRM analysis in our study. 
 
Table 2.9: Reagents and concentrations in PCR and HRM of the 24 DSP exons, the promoter 
region and the 5’ and 3’ UTRs 
REAGENT (STOCK CONCENTRATION) FINAL CONCENTRATION / VOLUME IN 
SOLUTION 
2X Reaction Mix (SensiMix Kit - 
Quantace) 
1X 
Forward Primer (20 µM) 0.2 µM 
Reverse Primer (20 µM) 0.2 µM 
DNA 100 ng 
EvaGreen dye (SensiMix Kit - Quantace) 1X 
FINAL REACTION VOLUME 25 µl 
 
Table  2.10: Optimised temperature cycling conditions for the PCR and HRM of the 24 DSP 










CONDITION TEMPERATURE (TIME) 




                  95°C - 5 seconds 
                  55°C -10 seconds      50 cycles 
                 72°C - 10 seconds 
High Resolution Melt 




2.5.4. Sequence Analysis 
DNA sequencing was performed on all samples that showed a change relative to the controls 
with HRM analysis. 
 
2.5.4.1. The principle of DNA sequence analysis 
DNA sequencing allows the determination of the order of base pairs in a specific DNA molecule.  
The procedure requires the DNA of interest to be mixed in solution with DNA polymerase, 
deoxynucleotide triphosphates (dNTPs), four labelled dideoxynucleotide triphosphates 
(ddNTPs) and a sequence-specific oligonucleotide primer.  The oligonucleotide primer directs 
the amplification of the DNA strand of interest, using dNTPs, ddNTPs and Taq polymerase.  
ddNTPs are incorporated into the forming DNA strand in a similar manner to dNTPs, but this 
incorporation causes the termination of the strand.  Temperature cycling similar to that used in 
PCR is used for the sequencing reaction (Hartwell et al. 2004) 
A complete series of single-stranded sub-fragments which are complementary to parts of the 
DNA strand of interest is generated, which can be separated by capillary electrophoresis in 
order to determine the DNA sequence of this strand (Luckey et al. 1990).  
 
2.5.4.2. Purification of HRM products 
After analysis by HRM, the samples were purified using the Shrimp Alkaline Phosphatase and 
Exonuclease I enzymes. The reagents used are shown in Table 2.5 and the reaction conditions 
are shown in Table 2.6. 
 
Table  2.11:  Cleanup protocol for DSP HRM products 
REAGENT QUANTITY 
Exonuclease I (New England Biolabs) 1 U 
Shrimp Alkaline Phosphatase (Promega) 2 U 
HRM Product 5 µl 
FINAL REACTION VOLUME 20 µl 
 
Table 2.12: Cycling conditions for the cleanup reactions of DSP HRM products 
CONDITION TEMPERATURE (TIME) 
Incubation 37°C - 1 hour 




2.5.4.3. Sequencing of DSP exons 
The reagents used for the direct sequencing reaction of the DSP exons are described in Table 
2.7.  The temperature cycling conditions used for the sequencing reactions are as described in 
Table 2.8. 
Table  2.13: PCR protocols for the sequencing reactions of DSP amplicons 
REAGENT FINAL CONCENTRATION / VOLUME IN 
SOLUTION 
Forward Primer (20 µM) 2 μM 
HRM product 3 μl 
BigDye ® Terminator v3.1. Ready Reaction 
Mix (Applied Biosystems) 
2 μl 
5 X Sequencing Buffer (Applied 
Biosystems) 
1 X 
FINAL REACTION VOLUME 20 µl 
 
Table  2.14: Optimised cycling conditions for the sequencing reactions of DSP amplicons 
CONDITION TEMPERATURE (TIME) 




                    96°C - 30 seconds 
                    50°C - 15 seconds      25 cycles 
                    60°C - 4 minutes 
2.5.4.4. Capillary electrophoresis 
The sequencing products were analysed using capillary electrophoresis at the DNA Sequencing 
Unit (Department of Genetics, Stellenbosch University), by means of the ABI PRISM® 3130xl 
Genetic Analyser (Applied Biosystems) or the ABI PRISM® 3730xl Genetic Analyser (Applied 
Biosystems). 
2.5.4.5. Sequence alignment and analysis 
The DNA sequences generated in these experiments were aligned with the wildtype sequence 
obtained from the Ensembl database (http://www.ensembl.org/) using the BioEdit Sequence 
Alignment Editor (© Tom Hall). 
 
2.6. POPULATION SCREENING 
Novel variants found using HRM analysis were confirmed by DNA sequencing.  Population 
screening was conducted to determine the prevalence of these variants in the normal control 
population. The cohort used for population screening included individuals from four South 
African ethnic groups: Caucasian, Mixed Ancestry, Black African and Indian. 
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For the ARVC novel variants, population screening was done by (1) restriction digests, using 
various restriction enzymes, or (2) by means of HRM. 
For the DCM novel variants, population screening was conducted using HRM analysis as 
described in section 2.5.  
 
2.6.1. Restriction Enzyme Digests 
Restriction enzyme digests were performed for population screening of novel variants found in 
the ARVC cohort. 
 
2.6.1.1. The principle of restriction enzyme digests 
Restriction enzymes are proteins made by bacteria that recognise specific, short nucleotide 
sequences and cut DNA at those sites. Restriction enzymes are divided into three types: I, II and 
III. Types I and III are ATP-dependent while type II is not. Type II restriction enzymes cut within 
or near specific nucleotide sequences that they recognise. 
In this project, type II restriction enzymes were used to determine the presence of a particular 
DNA sequence variant. They were used to determine the presence of single nucleotide changes 
e.g. if the change is present, and there is an A nucleotide base at the position of interest, the 
restriction enzyme would recognise that sequence and cleave the DNA at that site or a site near 
to it. In the control sample, where there is a G base at that position, the restriction enzyme will 
not recognise any sequence and will thus not cleave the DNA at that position. Hence, DNA 
sequence changes can be distinguished using this method. 
The DNA sequence of interest is first amplified using a method such as PCR, and the PCR 
product is then restriction digested by the enzyme selected for the experiment. If a restriction 
enzyme is not available at this site, a primer is designed that specifically incorporates a 
restriction site.  After the restriction digest reaction, the samples are run on an agarose gel to 
separate the fragments by size, and hence determine whether the DNA sequence change is 
present or not, based on the presence or absence of DNA cleavage by the restriction enzymes.  
 
2.6.1.2. Restriction enzyme digest protocol 
The PCR protocol is described in Tables 2.9 – 2.11. The amplicons generated during PCR were 
digested with VspI (Promega), FokI (Promega), PvuII (Fermentas) or HphI (New England Biolabs) 






Table 2.15: PCR Amplification protocol for DSP 
REAGENT (STOCK CONCENTRATION) FINAL CONCENTRATION / VOLUME IN 
SOLUTION 
Forward Primer (20 µM) 0.8 µM 
Reverse Primer (20 µM) 0.8 µM 
dNTPs (20 µM) (Bioline ) 0.8 µM 
GoTaq Polymerase (5U/ ul ) (Promega) 0.5 U 
GoTaq FlexiBuffer (5X) (Promega) 1 X 
MgCl2 (25 mM) (Promega) 1.5 mM 
DNA 200 ng 
FINAL REACTION VOLUME 25 µl 
 
Table 2.16: Optimised cycling conditions for the PCR of the DSP amplicons to be restriction 
digested by VspI, FokI and PvuII 
CONDITION TEMPERATURE (TIME) 




                            94°C - 30 seconds 
                              *     - 45 seconds      33 cycles 
                            72°C - 50 seconds 
Final Template Elongation 72°C - 7 min 
* Refer to Table 2.11 
 
Table 2.17: Primer annealing conditions for the PCR of amplicons for restriction digests 
ENZYME ANNEALING TEMPERATURE FOR PCR OF 














2.6.1.3. Agarose gel electrophoresis 
After the PCR was completed, the products were run on a 1.5% agarose gel at 160V to verify 
the success of the PCR amplifications. The samples were loaded into the wells of agarose gels 
with loading buffer (Appendix 2). Gel electrophoresis is used to separate DNA fragments of 
different sizes in an agarose gel (Appendix 2).  The DNA is negatively charged and migrates 
towards a positive electrode, allowing the separation of the DNA fragments according to size 
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(Hartwell et al. 2004).  The gel is submerged in 1X TBE buffer (Appendix 2) and run with a 
marker alongside the DNA fragments of interest.  The marker is a solution containing DNA 
fragments of known sizes, and is used as a guide in determining the size of the relevant DNA 
fragments.  The marker used in this study was the 100bp DNA Ladder (Promega) (Appendix 3). 
Restriction digested products were run on a 3% agarose gel (Appendix 2) using the same 
protocol used to run PCR products on an agarose gel, in order to determine the sizes of 
fragments resulting from enzyme cleavage. 
 
2.7. MULTIPLEX LIGATION-DEPENDENT PROBE AMPLIFICATION 
Multiplex ligation-dependent probe amplification (MLPA) is a variation of the polymerase chain 
reaction that allows the detection of abnormal copy numbers of up to 50 different DNA or RNA 
sequences. In this study, MLPA was performed on ARVC samples which were screened for DSP 
changes, using the SALSA MLPA Kit P168 ARVC-PKP2. 
 
2.7.1. The principle of MLPA 
In MLPA, it is not the target sequences that are amplified but instead the MLPA probes that 
hybridise to the target sequence. A single pair of primers is used to amplify multiple targets. 
The MLPA procedure can be divided into five major steps: (1) DNA denaturation and 
hybridisation of MLPA probes, (2) Ligation reaction, (3) PCR reaction, (4) Separation of 
amplification products by capillary electrophoresis, and (5) Data analysis. 
In the first step, the sample DNA is denatured and incubated overnight with a mixture of MLPA 
probes (Figure 2.4). The MLPA probes consist of two separate oligonucleotides each of which 
contain one of the PCR primer sequences. The probes recognise adjacent target sites on the 
DNA. One of the probes contains the sequence recognised by the forward primer and the other 
contains the sequence recognised by the reverse primer. Only when both of the probes are 
hybridised can they be ligated into a single probe in the ligation reaction (step 2). Only the 
ligated probes will be amplified exponentially during the PCR reaction (step 3), and hence the 
number of the probe ligation products is a measure of the number of target sequences present 
in the sample. The amplification products are then separated by capillary electrophoresis (step 
4). A universal primer pair is used to amplify all the MLPA probes, and each MLPA probe has a 
specific size (due to the unique stuffer sequence for each probe) which allows the different 






Figure 2.11: MLPA procedure (Info from http://www.mrc-holland.com) 
The MLPA kit used in this project was the SALSA MLPA Kit P168 ARVC-PKP2. This kit is designed 
to detect deletions/duplications of one or more exons of the PKP2, DSP, JUP, TGFβ3 and RyR2 
genes. MLPA can however also detect point mutations very close to the probe ligation site. The 
probemix in this kit contains 18 probes for PKP2, 7 probes for DSP and 3 probes each for JUP, 
TGFβ3 and RyR2 (Appendix 4). 
 
2.7.2. MLPA Protocol 
The MLPA reactions were carried out according to the manufacturer’s instructions (MRC 
Holland). The thermocycler used was a LabNet MultiGene™ thermocycler. 
 
1. DNA denaturation and hybridisation of the MLPA probes: 
The DNA sample is diluted in dH2O. 3 µl of DNA (100 ng/ µl) and 2 µl of dH2O are added to a PCR 
tube, and this mixture is then heated to 98°C for 5 minutes, then cooled to 25°C before opening 
the thermocycler. Thereafter, 1.5 µl SALSA probemix (MRC Holland) and 1.5 µl MLPA buffer 
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(MRC Holland) are added to the tube, and mixed thoroughly. This is then incubated at 95°C for 
1 minute and then left to hybridise overnight at 60°C for 16-20 hours. 
 
2. Ligation reaction 
Ligase-65 mix is prepared. This includes 3 µl Ligase-65 buffer A (MRC Holland), 3 µl Ligase-65 
buffer B (MRC Holland), 25 µl dH2O and 1 µl Ligase-65 (MRC Holland). The thermocycler is 
cooled to 54°C and the Ligase-65 mix is added. This is then incubated at 98°C for 5 minutes. 
 
3. PCR reaction 
In new tubes, 4 µl SALSA PCR buffer (MRC Holland) and 4 µl of dH2O are added. 10 µl of the 
MLPA ligation reaction product is added to these new PCR tubes and incubated at 60°C. 
Polymerase mix is prepared and contains 2 µl SALSA PCR-primers (MRC Holland), 2 µl SALSA 
Enzyme Dilution Buffer (MRC Holland), 5.5 µl dH2O and 0.5 µl SALSA Polymerase. This 
polymerase mix is then added to the PCR tube and the PCR reaction is immediately started. The 
PCR conditions are listed in Table 2.12. 
 
Table 2.18: Cycling conditions for the PCR reaction forming part of the MLPA protocol 




                   95°C - 30 seconds 
                   60°C - 30 seconds         35 cycles 
                   72°C - 60 seconds 
Template Elongation                    72°C - 20 minutes 
 
4. Running MLPA products on the ABI 3100 Genetic Analyzer 
8.6 µl Hi-Di™ Formamide (Applied Biosystems) and 0.4 µl GeneScan™ 500 ROX™ Size Standard 
(Applied Biosystems) is added to 1 µl MLPA product. This mixture is denatured at 95°C for 5 
minutes then snap-frozen on ice and run on the ABI 3100 Genetic Analyzer (Applied 
Biosystems). The data is then analysed using GeneMapper® version 3.0 (Applied Biosystems) 
and Coffalyzer version 8 (MRC-Holland) software. 
 
2.8. BIOINFORMATIC ANALYSIS 
Samples that were found to have sequence changes not reported in NCBI’s dbSNP database 
(http://www.ncbi.nlm.nih.gov/projects/SNP/) after sequencing analysis were analysed using 
various bioinformatic tools in order to determine whether they were likely to affect mRNA 




2.8.1. Bioinformatic Analysis of the Effect of Nucleic Acid Substitutions on Exon/Intron Splice 
Sites 
Once mRNA is transcribed from DNA, it undergoes specific post-transcriptional modifications that 
ensure correct gene expression. One of these modifications is mRNA splicing, in which the 
introns are removed from the mRNA and the exons are joined to form the processed transcript 
that will be translated into the protein. Correct splicing of the exon and intron requires a 5’ 
splice site at the beginning of the intron (with the sequence GT, known as the splice donor site), 
a 3’ splice site at the end of the intron (with the sequence AG, known as the splice acceptor 
site) and a branch site. Sequence changes which alter these sites could alter mRNA splicing. 
In order to determine whether novel sequence changes caused a change in mRNA splicing, the 
sequences were analysed using the Berkeley Drosophila Genome Project NNSPLICE 0.9 
(http://www.fruitfly.org/seq_tools/splice.html), SplicePort 
(http://spliceport.cs.umd.edu/SplicingAnalyser2.html) (Dogan et al. 2007) and NetGene2 
(http://www.cbs.dtu.dk/services/NetGene2/) (Hebsgaard et al. 1991) web-based tools. These 
tools allow the prediction of donor and acceptor splice sites in a particular sequence.  
 
2.8.2. Bioinformatic Analysis of the Effect of Nucleic Acid Substitutions on Exonic Splice 
Enhancer (ESE) Sites 
In addition to the canonical splice sites mentioned above, other cis-elements exist in the form 
of splicing enhancers and silencers (Cartegni et al. 2003). These elements are especially 
important in the event of alternative splicing. Mutations that disrupt these elements could 
cause skipping of the mutant exon, with dramatic effects on the gene product. 
In order to determine whether novel sequence changes could disrupt existing ESEs, sequences 
were analysed using the ESEFinder web-based tool (http://rulai.cshl.edu/cgi-
bin/tools/ESE3/esefinder.cgi?process=home) (Cartegni et al. 2003). This tool allows the 
prediction of ESEs that act as binding sites for Ser/Arg-rich proteins (SR proteins), a family of 
conserved splicing factors that participate in the splicing pathway. 
 
2.8.3. Bioinformatic Analysis of the Effect of Nucleic Acid Substitutions on the Secondary 
Structure of RNA 
Changes in the DNA sequence, and consequent changes in the transcribed RNA, could affect 
RNA folding and RNA secondary structure. Sequences were analysed using the Mfold 
(http://mfold.bioinfo.rpi.edu/cgi-bin/rna-form1.cgi) (Zuker 2003) and RNAfold 
(http://rna.tbi.univie.ac.at/cgi-bin/RNAfold.cgi) (Hofacker 2003) web-based tools to predict 
RNA folding. Mfold can be used to predict optimal and suboptimal secondary structures of RNA 
molecules using energy minimisation criteria developed by the creators. RNAfold performs a 
similar function, in that it can be used to predict the minimum free energy structure of a single 
sequence. It can however also be used to calculate the equilibrium base-pairing probabilities of 
this sequence.  
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2.8.4. Bioinformatic Analysis of the Effect of Amino Acid Substitutions on Protein Structure 
Mutations that lead to a change in the protein sequence could affect the secondary structure of 
protein. In the case of mutations that affect the protein sequence, the PSIPRED protein 
structure prediction server (http://bioinf.cs.ucl.ac.uk/psipred/) was used to predict the 
secondary structure of the protein based on the protein sequence (McGuffin et al. 2000). 
PSIPRED incorporates two feed-forward neural networks which perform an analysis on output 
obtained from PSI-BLAST (Position-Specific Iterated Basic Local Alignment Search Tool) 
(McGuffin et al. 2000).  
The Align-GVGD (http://agvgd.iarc.fr/agvgd_input.php) (Tavtigian et al. 2006), POLYPHEN 
(POLYmorphism PHENotyping) (http://genetics.bwh.harvard.edu/pph/) (Ramensky et al. 2002) 
and SIFT (Sorting Intolerant From Tolerant) (http://sift.jcvi.org/) (Ng and Henikoff 2003) 
bioinformatic tools were used to predict whether non-synonymous mutations had deleterious 
effects on the protein. The Align-GVGD program uses calculations that are an extension of the 
Grantham Difference and take into account the polarity, position and volume of amino acids 
(Mathe et al. 2006). It calculates the biochemical difference between a mutant amino acid and 
the observed variation at that position in order to determine whether or not the variant is 
deleterious. The POLYPHEN tool predicts whether a mutation is disease-causing based on a set 
of rules that are applied to the sequence, structural and phylogenetic information 
characterising the amino acid substitution (Ramensky et al. 2002). The SIFT tool calculates the 
probability of an amino acid being found at a specific position relative to the most frequent 

















3.1. MUTATION SCREENING OF DSP 
The ARVC and DCM probands selected for this study were screened for mutations in the 24 
exons of the DSP gene, the 5’ and 3’ untranslated regions (UTRs) as well as the promoter region 
(as predicted by the Gene2Promoter tool) by means of high resolution melt (HRM) and 
multiplex ligation-dependent probe amplification (MLPA) analyses.  We performed mutation 
screening in 62 probands with ARVC, 19 index cases with familial DCM and 131 unrelated cases 
of apparently sporadic DCM (Table 3.1) (a total of 212 individuals). 
In the ARVC cohort, 32% were female while 68% were male. In the DCM cohort 37% were 
female while 63% were male. The average age (±SD) of the probands in the ARVC cohort was 41 
± 16 years, while the average age of the DCM probands was 47 ± 16 years. In the ARVC cohort, 
the majority of patients were of Caucasian ethnicity, while in the DCM cohort, the majority 
were of Black African ethnicity. These samples were screened in conjunction with ethnicity 
matched population control samples from anonymous blood donors from the blood transfusion 
bank of the Western Cape Province of South Africa. 
 
Table 3.19: Age, Gender and Diagnosis of Study Participants 
CHARACTERISTIC ARVC PATIENTS DCM PATIENTS 
No. of Patients 62 (%) 
































3.1.1. Mutation screening of the ARVC Cohort 
ARVC samples were screened using high resolution melt analysis (see Appendix 5 for detailed 
explanation of the various experiments). Samples showing differences in melting behaviour 
relative to the control samples were sequenced in order to determine the nature of these 
changes. A number of DNA sequence variants were found in the ARVC cohort (Table 3.2). These 
included six novel variants, one known rare variant and 22 known common 
variants/polymorphisms. 
RNAfold and MFOLD bioinformatic analysis tools were used to predict whether the novel DSP 
variants and  the known rare variant caused structural changes in the mRNA, while the 
ESEFinder tool was used to predict whether variants affected mRNA splicing, by determining 
whether variants affected exonic splice enhancers (ESEs). The PSIPRED bioinformatic tool was 
used to predict if these variants caused changes in the secondary structure of the DSP protein, 
while the POLYPHEN, SIFT and Align GVGD bioinformatic tools were used to determine whether 
these variants had a deleterious effect on the DSP protein (Fressart et al. 2010). 
Population screening was conducted on all novel variants and the known rare ARVC variants in 
order to determine their prevalence in the South African population. High resolution melt 
analysis and DNA sequencing, or restriction digests were used. The control cohort consisted of 
200 individuals (400 chromosomes) who belonged to the four main South African ethnic groups 
(Cape Mixed Ancestry (98), Black African (63), Indian (29) and Caucasian (10)).  
The variants identified in this cohort were classified as (1) Causal mutations, (2) Genetic 
Variants of Unknown Significance, or (3) Polymorphisms using a system based on the criteria 
described by Fressart and colleagues (Fressart et al. 2010); this system was extended to include 
bioinformatic tools for the prediction of mRNA secondary structure, ESE consensus sequences 
and protein secondary structure.   
A genetic variant was considered to be a causal mutation on the basis of (1) the absence of the 
variant in the control population (and in SNP databases), (2) alteration of conserved amino 
acids (in certain cases), (3) prediction by bioinformatic tools that the variant would cause 
changes in mRNA folding, mRNA splicing or protein secondary structure, (4) prediction by the 
POLYPHEN, SIFT and Align GVGD tools that the variant would be deleterious to the DSP protein, 
and (5) segregation with disease where family information was available. A genetic variant was 
considered as a Genetic Variant of Unknown Significance (GVUS) in the presence of a missense 
variant which was absent or rare (i.e., <1%) in the control population but without a causal effect 
predicted by at least one software or with a mutated residue that is not highly conserved 
among species/isoforms. A genetic polymorphism was defined as a variant observed in the 




















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































3.1.1.1. Novel variants in the ARVC cohort 
The six novel changes detected in the ARVC cohort were found to be exonic: three non-
synonymous and three synonymous changes (Table 3.2). For probands where novel variants 
were found, their first degree relatives were screened for these specific variants (if the DNA 
samples were available) to determine the segregation pattern of the variants with disease.  
3.1.1.1.1. c.860A>G variant 
In exon 7 of DSP, we detected a novel c.860A>G transition that caused the amino acid to 
change from asparagine (N) to serine (S) (p.N287S) (Figure 3.1). This mutation occurred in one 
ARVC proband (ACM 6.1), who was a male of Mixed Ancestry. Orthologous alignment of the 
Homo sapiens protein sequence to other modern species found that the amino acid is highly 
conserved. This missense mutation was predicted to have a deleterious effect on the DSP 
protein by the SIFT and Align-GVGD bioinformatic tools. Population screening for this variant 
was conducted by means of restriction digest by the VspI enzyme.  The results showed that the 
variant was absent in the control population. Based on the fact that this variant (i) was not 
found in the control population, (ii) was shown to alter a conserved amino acid and (iii) was 
predicted to have a deleterious effect on the protein by SIFT and Align-GVGD, we concluded 
that this variant is causative of ARVC. 
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Figure 3.12: Results of c.860A>G: (A) HRM graph showing the exon 7 melting curve of DSP in the 
control samples and patient sample (B) Derivative graph of (A)(C) Sequencing electropherogram 
showing the c.860A>G sequence change (D) Multiple species protein alignment of this sequence 
C 
              Control 
              Control 
              Variant 
H. sapiens      QATSREIMWINDCEEEELLYD         
P. troglodytes  QATSREIMWINDCEEEELLYD     
B. taurus       QATSREIMWINDCEEEELLYD 




3.1.1.1.2. c.1344G>A variant 
In exon 11 of DSP, we detected a novel c.1344G>A transition; this did not result in an amino 
acid change (p.L448) (Figure 3.2). This mutation occurred in one ARVC proband (ACM 8.3), who 
was a female of Caucasian origin.  RNAfold predicted that the c.1344G>A variant destabilized 
the mRNA secondary structure, which could result in mRNA degradation (Figure 3.3). 
Population screening for this variant was conducted by means of restriction digest by the PvuII 
enzyme, and revealed the variant to be absent in the control population. 
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Figure 3.13: Results of c.1344G>A: (A) HRM graph showing the exon 11 melting curve of DSP in 
the control samples and patient sample (B) Derivative graph of (A); (C) Sequencing 
electropherogram showing the c.1344G>A sequence change 
              Control 
              Control 








The discovery of this variant resulted in the screening of the available family members of this 
proband (Family ACM 8); this included an affected brother, both parents, the mother’s sister 
and her husband and two daughters (ACM 8.1, 8.2 and 8.4 - 8.8) (Figure 3.4). These family 
members, with the exception of the proband’s brother, were considered to be clinically 
unaffected with ARVC at the time of genetic testing. Of these individuals, only the proband’s 
mother was found to carry this variant. Although this variant (i) was absent in the control 
population and (ii) was predicted to alter mRNA secondary structure by the RNAfold tool, it (i) 
did not alter an amino acid, and (ii) does not segregate with disease in this family. Therefore, 
we concluded that this variant was unlikely to be disease-causing, but it could serve as a 
modifier of gene function. We classified this mutation as a Genetic Variant of Unknown 
Significance at this stage. 
 
Figure 3.14: RNAfold results of 
c.1344G>A: (A) Exon 11 control 
and (B) Exon 11 with c.1344G>A 
variant mRNA folding structures 











ACM 8.5 ACM 8.6
ACM 8.7 ACM 8.8
 
Figure 3.15: Pedigree of family ACM 8 showing variant c.1344G>A and individuals with ARVC 
 
3.1.1.1.3. c.1534A>G variant 
In exon 12 of DSP, we detected a novel c.1534A>G transition that caused the amino acid to 
change from isoleucine (I) to valine (V) (p.I512V) (Figure 3.5). This mutation occurred in one 
ARVC proband (ACM 56.1), who was a female of Black African ethnicity. Orthologous alignment 
of the Homo sapiens protein sequence to other modern species found this amino acid to be 
highly conserved. MFOLD and RNAfold revealed that the c.1534A>G sequence variant caused a 
predicted change in mRNA secondary structure which could result in destabilized mRNA and 























































H. sapiens    DMLVPSVGLIIPPPNPLAVDLS 
P. troglodytes  DMLVPSVGLIIPPPNPLAVDLS 
B. taurus     DMLVPSVGLIIPPPNPLAVDLS 
M. musculus    DMLVPSVGLIIPPPNPLAVDLS 
 
 
Figure 3.16: Results of c.1534A>G: (A) HRM graph showing the exon 12 melting curve of DSP in 
the control samples and patient sample (B) Derivative graph of (A); (C) Sequencing 
electropherogram showing the c.1534A>G sequence change; (D) Multiple species protein 
alignment of this sequence. 
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              Control 






    
 
    
Figure 3.17: MFOLD and RNAfold results of c.1534A>G: (A) Exon 12 control and (B) Exon 12 with 
c.1534A>G variant mRNA folding structures predicted by mFold. (C) Exon 12 control and (D) 





Figure 3.18: Results of c.4022G>A: (A) HRM graph showing the exon 12 melting curve of DSP in 
the control samples and patient sample (B) Derivative graph of (A); (C) Sequencing 
electropherogram showing the c.4022G>A sequence change (sequenced with reverse primer); 
(D) Multiple species protein alignment of this sequence 
 
Population screening for this variant was conducted by means of restriction digest by the FokI 
enzyme, and revealed the variant to be absent in the control population. Based on the fact that 
(i) the variant is absent in the control population, (ii) it alters a conserved amino acid and (iii) 
was predicted to alter mRNA secondary structure by MFOLD and RNAfold, we conclude that 
this variant is causative of ARVC. 
3.1.1.1.4. c.4022G>A variant 
In exon 23 of DSP, we detected a novel c.4022G>A transition that caused the amino acid to 
change from an arginine (R) to histidine (H) (p.R1341H) (Figure 3.7). This missense mutation 
occurred in one ARVC proband (ACM 34.5), who was a male of Mixed Ancestry. Orthologous 
alignment of the Homo sapiens protein sequence to other modern species found that the 
amino acid is highly conserved. ESEFinder found that the c.4022G>A variant in exon 12 is 
predicted to disrupt an SRp40 consensus sequence (Figure 3.8).  
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H. sapiens    KAEFQEEAKRRWEYENELSKV 
P. troglodytes  KAEFQEEAKRRWEYENELSKV 
B. taurus     KTEFQEEAKRRWEYENELAKV 
M. musculus    KAEYQEEAKRRWEYENELSKV 
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              Control 






       
 
Figure 3.19: ESE results of c.4022G>A: (A) Exon 23 control ESE analysis; (B) Exon 23 c.4022 G>A 
variant ESE analysis 
 
This variant is predicted to have a deleterious effect on the DSP protein by the SIFT and Align-
GVGD bioinformatic tools but and was found at a frequency of 0.75% in the control population. 
Although the variant was predicted to (i) alter a conserved amino acid, (ii) alter an ESE 
consensus sequence by the ESEFinder tool and (iii) have a deleterious effect on the DSP protein 
by the SIFT and Align GVGD tools, it was found at a low frequency of 0.75% in the control 
population. Based on the detection of the variant in apparently normal controls, albeit below 
the 1% frequency of a polymorphism, we classified this variant as a Genetic Variant of Unknown 
Significance at this stage. 
 
3.1.1.1.5. c.8199G>C variant 
We detected a novel c.8199G>C transversion in exon 24 of ACM33.2; this substitution did not 
cause an amino acid change (p.T2733) (Figure 3.9). This mutation occurred in one ARVC 
proband (ACM 33.2), who was a male of Caucasian ethnicity.  Population screening for this 
variant was conducted by means of restriction digest by the HphI enzyme, and revealed the 
variant to be absent in the control population. Furthermore, it did not alter an amino acid and 
was not predicted to alter mRNA secondary structure, ESE consensus sequences or protein 
secondary structure or have a deleterious effect on the DSP protein. We have classified this 














































Figure 3.20: Results of c.8199G>C: (A)  HRM graph showing the exon 24 melting curve of DSP in 
the control samples and patient sample (B) Derivative graph of (A); (C) Electropherogram 
showing the c.8199G>C sequence change 
 
3.1.1.1.6. c.8539A>C variant 
We also detected a second novel sequence variant in ACM 34.5. In exon 24 of DSP, we detected 
a novel c.8539A>C transversion that did not cause the amino acid to change (p.R2847) (Figure 
3.10). This mutation occurred in one ARVC proband (ACM 34.5). MFOLD predicted that the 
mutated mRNA sequence would cause a change in the mRNA secondary structure of this gene 
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Figure 3.21: Results of c.8539A>C: (A) HRM graph showing the exon 24 melting curve of DSP in 
the control samples and patient sample (B) Derivative graph of (A); (C) Sequencing 
electropherogram showing the c.8539A>C sequence change  
              Control 
              Control 





     
Figure 3.22: MFOLD results of c.8539A>C: (A) Exon 24 control and (B) Exon 24 with c.8539A>C 
variant mRNA folding structures 
Population screening revealed that this variant was absent in the control population. Although 
this variant (i) was absent in the control population and (ii) was predicted to alter mRNA 
secondary structure by the MFOLD tool, it was a silent mutation that did not alter an amino 
acid. We have not yet been able to conduct direct analysis of the mRNA of the proband to rule 
out a cryptic splice site that may be introduced by this variant due to unavailability of an 
appropriate sample (Awad et al. 2006). Therefore, we concluded that this was a Genetic Variant 
of Unknown Significance at this stage. 
3.1.1.2. Known variants in the ARVC cohort 
Twenty three reported variants were found in the ARVC cohort. These included one rare 
variant, 12 common intronic variants and 10 common exonic variants (eight synonymous and 







3.1.1.2.1. Rare known variants 
The one known rare DNA sequence change (c.105G>A transition) was detected in exon 1 of DSP 
(Figure 3.12). Even though the variant had been reported in the ARVC database 
(http://www.arvcdatabase.info/), no further information was available about its causal role or 
otherwise in ARVC.  The sequence change did not result in an amino acid change (p.35G). This 
mutation occurred in one ARVC proband (ACM 33.2). MFOLD revealed that the c.105G>A 
variant caused a predicted change in mRNA secondary structure (Figure 3.13).  
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Figure 3.23: Results of c.105G>A: (A) 
HRM graph showing control samples 
and variant sample amplicon 
melting; (B) Derivative graph of (A); 
(C) Electropherogram showing the 

















This variant was absent in the control population. Although (i) this variant was absent in the 
control population and (ii) was predicted to alter mRNA folding by the MFOLD tool, it has not 
been possible to conduct direct analysis of mRNA  to rule out a cryptic splice site due to 
unavailability of appropriate samples (Awad 2006). We have therefore classified it as a Genetic 
variant of Unknown Significance at this stage. 
 
3.1.1.2.2. Common known variants / polymorphisms 
The 22 common known variants found in the ARVC cohort included 12 intronic variants and 10 
exonic variants (eight synonymous and two non-synonymous changes) (Table 3.3). As these 
variants are reported in NCBI’s single nucleotide polymorphism (SNP) database 
(http://www.ncbi.nlm.nih.gov/projects/SNP/), they were not screened for in our control 
population. Of these, eight variants had a minor allele frequency of <5% in our ARVC cohort, 
while the other 14 had a minor allele frequency of >5%. 
All variants discovered in the ARVC cohort were summarised in Table 3.3 using the extended 
Fressart criteria (Fressart et al. 2010) as described in section 3.1.1.  
A B Figure 3.24: MFOLD results 
of c.105G>A: (A) Exon 1 
control and (B) Exon 1 with 
the c.105G>A variant mRNA 





Table 3.21: Classification of ARVC Variants according to extended Fressart criteria 
 
 










Exon 7 - c.860A>G p.N287S 0 Causal variant 
Exon 11 - c.1344G>A p.L448 0 Genetic Variant of Unknown Significance 
Exon 12 - c.1534A>G p.I512V 0 Causal variant 
Exon 23 - c.4022G>A p.R1341H 0.75 Genetic variant of Unknown Significance 
Exon 24 
- c.8199G>C p.T2733 0 Genetic Variant of Unknown Significance 
- c.8539A>C p.R2847 0 Genetic Variant of Unknown Significance 
Reported Variants 
Rare Variant 
Exon 1 - c.105G>A p.35G 0 Genetic Variant of Unknown Significance 
Polymorphisms (reported in dbSNP database) 
Promoter - rs2076298 c.1-538G>C - - Polymorphism 
Intron 1 rs9392904 c.171-97G>C - - Polymorphism 
Intron 2 rs10484326 c.274-31T>C - - Polymorphism 
Exon 6 rs2806234 c.741T>G p.A247 - Polymorphism 
Exon 7 rs17604693 c.913A>T p.I306F - Polymorphism 
Intron 9 rs2076296 c.1141-44C>T - - Polymorphism 
Intron 14 rs926411 c.1903+57G>A - - Polymorphism 
Intron 15 rs2076303 c.1904-49T>A - - Polymorphism 
Exon 15 rs2076304 c.2091A>G p.G697 - Polymorphism 
Intron 16 rs7741957 c.2297+51T>C - - Polymorphism 
Exon 20 rs2064217 c.2862C>T p.C954 - Polymorphism 
Intron 20 rs2064218 c.2877+79C>A - - Polymorphism 
Intron 21 rs6942260 c.2984+70G>A - - Polymorphism 
Intron 22 rs6905839 c.3084-72G>A - - Polymorphism 
Exon 23 
rs28763964 c.3510G>A p.E1170 - Polymorphism 
rs61731476 c.3963G>A p.Q1321 - Polymorphism 
rs28763968 c.4773G>A p.R1591 - Polymorphism 
rs6929069 c.5213G>A p.R1738Q - Polymorphism 
Exon 24 
rs11558731 c.8175C>A p.R2725 - Polymorphism 
rs2744380 c.8472G>C p.G2824 - Polymorphism 
3’UTR - 
rs11558732 c.8616+9T>A - - Polymorphism 
rs12250 c.8616+197C>T - - Polymorphism 
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3.1.2. Mutation screening of the DCM Cohort 
DCM samples were screened using high resolution melt analysis and DNA sequencing in the 
same manner as the ARVC samples. A number of DNA sequence variants were found in the 
DCM cohort. These included 24 novel variants, three known rare variants and 16 known 
common variants/polymorphisms (Table 3.4). 
RNAfold, MFOLD, ESEFinder, PSIPRED, POLYPHEN, SIFT and Align GVGD bioinformatic analysis 
software tools were used to predict if any of these variants caused structural changes in the 
RNA, splicesomes, transcriptomes or protein structure/function. 
Population screens, for the novel and reported rare variants found in the DCM cohort, were 
conducted using high resolution melt analysis and DNA sequencing; for this, the same control 
cohort used for the ARVC population screens was used.  
The variants identified in this cohort were classified as (1) Causal mutations, (2) Genetic 
Variants of Unknown Significance or (3) Polymorphisms using the extended Fressart criteria 


























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































3.1.2.1. Novel variants in the DCM cohort 
In the DCM cohort, 24 sequence changes were found that had not been previously reported 
(Table 3.4). These variants included seven intronic variants and 17 exonic variants (six 
synonymous and 11 non-synonymous variants). The majority of these changes were found in 
patients with idiopathic DCM. Only one of the individuals with a novel sequence change (DCM 
296.1) was diagnosed with familial DCM. A few of the novel variants are discussed in more 
detail but information on the rest of the novel variants can be found in Table 3.4.  If a novel 
variant was detected in the proband and we had the DNA available of the nuclear family, these 
members were genetically tested for segregation of the variant with disease.  
 
3.1.2.1.1. c.1222A>C variant 
In exon 10 of the DSP gene, we detected a c.1222A>C transversion that caused an amino acid 
change from asparagine (N) to histidine (H) (N408H). This mutation occurred in only one DCM 
proband (DCM 173.1), who was a male of Mixed Ancestry ethnicity. Orthologous alignment of 
the Homo sapiens protein sequence to other modern species found that the amino acid is 
highly conserved. MFOLD and RNAfold revealed that this sequence variant caused a predicted 
change in mRNA secondary structure which could result in destabilized mRNA and premature 
mRNA degradation. ESEFinder found that this variant is predicted to disrupt an SF2/ASF 
consensus sequence, while the SIFT and Align GVGD tools predicted that this variant had a 
deleterious effect on the DSP protein. This variant was also found to be absent in the control 
population. Based on the fact that this variant (I) was absent from the control population, (ii) 
alters a conserved amino acid, (iii) was predicted to alter mRNA secondary structure by MFOLD 
and RNAfold, (iv) was predicted to alter an ESE consensus sequence by ESEFinder and (v) was 
predicted to have a deleterious effect on the DSP protein by SIFT and Align-GVGD, we conclude 
that this variant is causative of DCM. 
3.1.2.1.2. c.1228C>T variant 
In exon 10 of DSP, we detected a c.1228C>T transition that caused an amino acid change from 
phenylalanine to serine (p.P410S). This mutation was found in only one DCM proband (DCM 
158.1), who was a male of Black African ethnicity. Orthologous alignment of the Homo sapiens 
protein sequence to other modern species found that the amino acid is highly conserved. 
RNAfold revealed that this sequence variant caused a predicted change in mRNA secondary 
structure which could result in destabilized mRNA and premature mRNA degradation. The 
PSIPRED tool predicted that this variant would cause a change in protein secondary structure, 
while the Align GVGD tool predicted that this variant would have a deleterious effect on the 
DSP protein. Based on the fact that this variant (I) was absent in the control population, (ii) 
alters a conserved amino acid, (iii) was predicted to cause a change in mRNA secondary 
structure by RNAfold, (iv) was predicted to alter protein secondary structure by PSIPRED and (v) 
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was predicted to have a deleterious effect on the DSP protein by Align GVGD, we conclude that 
this variant is causative of DCM. 
3.1.2.1.3. c.2288A>G variant 
In exon 16 of DSP, we detected a c.2288A>G transition that caused an amino acid change from 
tyrosine (Y) to cysteine (C) (Y763C). This mutation was found in only one DCM proband (DCM 
58.1), who was a female of Black African ethnicity. Orthologous alignment of the Homo sapiens 
protein sequence to other modern species found that the amino acid is highly conserved. The 
SIFT, POLYPHEN and Align GVGD tools predicted that this variant would have a deleterious 
effect on the DSP protein. This variant was absent in the control population. Based on the fact 
that (i) the variant is absent in the control population, (ii) it alters a conserved amino acid and 
(iii) it was predicted to have a deleterious effect on the DSP protein by the POLYPHEN, SIFT and 
ALIGN GVGD tools, we conclude that this variant is causative of DCM. 
3.1.2.1.4. c.3085-2A>G variant 
In intron 22 of DSP, we detected a c.3085-2A>G transition that did not cause an amino acid 
change. This mutation occurred in only one DCM proband (DCM 301.1), who was a female of 
Black African ethnicity. This variant caused an alteration in the sequence at a 3’ intronic splice 
site, which would result in a change in mRNA splicing. RNAfold revealed that this sequence 
variant caused a predicted change in mRNA secondary structure which could result in 
destabilized mRNA and premature mRNA degradation. This variant was found to be absent in 
the control population. Based on the fact that (i) the variant is absent in the control population, 
(ii) it is a splice junction mutation (Shapiro and Senapathy 1987), and (iii) it was predicted to 
change mRNA secondary structure by RNAfold, we conclude that this variant is causative of 
DCM. 
3.1.2.1.5. c.3260A>C variant 
In exon 23 of DSP, we detected a c.3260A>C transversion that caused an amino acid change 
from glutamate (E) to alanine (A) (E1087A). This mutation occurred in only one DCM proband 
(DCM 301.1). Orthologous alignment of the Homo sapiens protein sequence to other modern 
species found that the amino acid is highly conserved. MFOLD and RNAfold revealed that this 
sequence variant caused a predicted change in mRNA secondary structure which could result in 
destabilized mRNA and premature mRNA degradation. The POLYPHEN and Align GVGD tools 
predicted that this variant had a deleterious effect on the DSP protein. This variant was found 
to be absent in the control population. Based on the fact that (i) the variant is absent in the 
control population, (ii) it alters a conserved amino acid, (iii) it was predicted to cause a change 
in mRNA secondary structure by MFOLD and RNAfold and (iv) it was predicted to have a 
deleterious effect on the DSP protein by the POLYPHEN and Align GVGD tools, we conclude that 
this variant is causative of DCM. 
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3.1.2.1.6. c.3806G>A variant 
One of the novel changes, a c.3806G>A transition in exon 23 of DSP, changed the amino acid 
from an arginine (R) to asparagine (N) (p.R1269N). This mutation was found in only one DCM 
proband (DCM 296.1), who was a female of Mixed Ancestry ethnicity. Orthologous alignment of 
the Homo sapiens protein sequence to that of modern species found that the amino acid is 
highly conserved. This variant was predicted to have a deleterious effect on the DSP protein by 
the POLYPHEN and Align GVGD tools, and was absent in the control population. Based on the 
fact that (i) the variant is absent in the control population, (ii) it alters a conserved amino acid 
and (iii) it was predicted to have a deleterious effect on the DSP protein by the POLYPHEN and 
ALIGN GVGD tools, we conclude that this variant is causative of DCM. 
 
3.1.2.2. Known variants in the DCM cohort 
In the DCM cohort, three rare reported DNA sequence variants and 16 common reported 
variants were identified. The three rare variants included two exonic, non-synonymous variants 
and one intronic variant. These changes (c.422+32C>T, c.2815G>A and c.5178C>A) had been 
reported in the ARVC database (http://www.arvcdatabase.info/); however, no further 
information was available about the causal role or otherwise of these mutations in ARVC. 
 
3.1.2.2.1 Rare known variants 
3.1.2.2.1.1. c.422+32C>G variant 
In intron 3 of DSP, we detected a c.422+32C>G transversion (Figure 3.14) which only occurred 

















































RNAfold revealed that this sequence variant caused a predicted change in mRNA secondary 
structure which could result in destabilized mRNA and premature mRNA degradation (Figure 
3.15).  
         
Figure 3.26: RNAfold results of c.422+32C>G: (A) Exon 3 with part of intron 3 control and (B) 
Exon 3 with part of intron 3 with c.422+32C>G variant mRNA folding structures predicted by 
RNAFold. 
              Control 
              Control 




Figure 3.25: Results of c.422+32C>G: (A) 
HRM graph showing control samples and 
variant sample amplicon melting; (B) 
Derivative graph of (A); (C) 
Electropherogram showing the 




This variant was absent in the control population. Although this variant (i) was not found in the 
control population and (ii) was predicted to alter mRNA secondary structure by RNAfold, its 
intronic position raises doubt about its pathogenic significance.  We have therefore classified it 
as a Genetic Variant of Unknown Significance at this stage. 
3.1.2.2.1.2. c.2815G>A variant 
In exon 20 of DSP, we detected a c.2815G>A transition that changed the amino acid from 
glycine (G) to serine (S) (p.G939S) (Figure 3.16). This change occurred in four DCM probands 
(DCM 31.1 (Black African male), DCM 35.1 (Black African female), DCM 59.1 (Male of Unknown 
ethnicity) and DCM 73.1 (Black African male)). Orthologous alignment of the Homo sapiens 
protein sequence to modern animal species found that the amino acid is highly conserved.  
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Figure 3.27: Results of c.2815G>A: (A) HRM graph showing control samples and variant sample 
amplicon melting; (B) Derivative graph of (A); (C) Electropherogram showing the c.2815G>A 
sequence change; (D) Multiple species protein alignment of this sequence 
              Control 
              Control 
              Variant 
H. sapiens    EQKNLHSEISGKRDKSEEVQK 
P. troglodytes  EQKNLHSEISGKRDKSEEVQK 
B. taurus     EQKNLHSEISGKRDKSEEVQK 







This variant was predicted to cause a change in protein secondary structure by the PSIPRED tool 
(Figure 3.17); it was also predicted to have a deleterious effect on the protein by the POLYPHEN 
and Align GVGD tools. However, this variant was found at a frequency of 1% in the control 




Figure 3.28: PSIPRED results of c.2815G>A: (A) PSIPRED predicted protein secondary structure 
of control; (B) PSIPRED predicted protein secondary structure of sequence with the c.2815G>A 
(p.G939S) variant (H – α-helix element; E – β-strand element; C – random coil element) 
 
3.1.2.2.1.3. c.5178C>A variant 
In exon 23 of DSP, we detected a c.5178C>A transversion that changed the amino acid from an 
asparagine (N) to lysine (K) (p.N1726K) (Figure 3.18). This mutation was found in only one DCM 
proband (DCM 241.1), who was a male of Indian ethnicity. Orthologous alignment of the Homo 


























































Figure 3.29: Results of c.5178C>A: (A) HRM graph showing control samples and variant sample 
amplicon melting; (B) Derivative graph of (A); (C) Electropherogram showing the c.5178C>A 
sequence change; (D) Multiple species protein alignment of this sequence 
 
 
MFOLD revealed that this sequence variant caused a predicted change in mRNA secondary 
structure which could result in destabilized mRNA and premature mRNA degradation (Figure 
3.19). The POLYPHEN and Align GVGD tools predicted that this variant would have a deleterious 
effect on the protein. This variant was absent in the control population. 
 
              Control 
              Control 




H. sapiens    EHLMLEEELRNLRLEYDDLRR 
P. troglodytes  EHLMLEEELRNLRLEYDDLRR 
B. taurus     EHLMLEEELRQLRLEYDDLQR 
M. musculus    EHLMLEEELRNLRLEYDDLRR 
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Figure 3.30: MFOLD results of c.5178C>A: (A) Exon 23 control and (B) Exon 23 with c.5178C>A 
variant mRNA folding structures predicted by mFold. 
               
The discovery of this mutation led to the genetic screening of the DNA of one deceased son 










DCM 241.2  
 
Figure 3.31: Pedigree of family DCM 241 showing variant c.5178C>A and individuals with DCM 
 
This family member was found to carry the c.5178C>A variant, and was found to be clinically 
affected with DCM at the time of genetic screening. Based on the fact that this variant (i) is 
absent in the control population, (ii) alters a conserved amino acid, (iii) was predicted to alter 
mRNA secondary structure by the MFOLD tool, (iv) was predicted to have a deleterious effect 
on the protein by the POLYPHEN and Align GVGD tools and (v) there is preliminary evidence of 
segregation with disease in this family, we conclude that this variant is causative of DCM. 
 
3.1.2.2.2 Common known variants 
The 16 common polymorphisms detected in the DCM cohort included nine intronic variants and 
seven exonic variants (four synonymous and three non-synonymous changes). As these variants 
are reported in the SNP database (http://www.ncbi.nlm.nih.gov/projects/SNP/), they were not 
screened for in our control population. Of these, three variants had a minor allele frequency of 
<5% in our DCM cohort, while the other 13 had a minor allele frequency of >5%. 
All variants discovered in the DCM cohort are summarised in Table 3.5 using the extended 




Table 3.23: Classification of DCM Variants according to the extended Fressart criteria 










Intron 3 - c.422+23C>T - 0 Genetic Variant of Unknown Significance 
Exon 5 - c.687C>T p.G229 1 Polymorphism 
Exon 7 - c.816G>A p.L272 1 Polymorphism 
Intron 8 - c.1043+32A>T - 0 Genetic Variant of Unknown Significance 
Exon 10 
- c.1222A>C p.N408H 0 Causal Variant 
- c.1228C>T p.P410S 0 Causal Variant 
Exon 12 
- c.1512T>C p.L504 1.50 Polymorphism 
- c.1534A>G p.I512V 0 Causal Variant 
Intron 13 - c.1701+54G>A - 1.75 Polymorphism 
Intron 14 
- c.1904-54C>T - 0 Genetic Variant of Unknown Significance 
- c.1904-12T>G - 1 Polymorphism 
Exon 15 
- c.1997C>T p.T666I 0.25 Genetic Variant of Unknown Significance 
- c.2121C>T p.N707 0.25 Genetic Variant of Unknown Significance 
Intron 15 - c.2130+63A>T - 0 Genetic Variant of Unknown Significance 
Exon 16 - c.2288A>G p.Y763C 0 Causal Variant 
Exon 19 - c.2773C>T p.R925W 1.25 Polymorphism 
Intron 22 - c.3085-2A>G - 0 Causal Variant 
Exon 23 
- c.3260A>C p.E1087A 0 Causal Variant 
- c.3806G>A p.R1269N 0 Causal Variant 
- c.4022G>A p.R1341H 0.75 Genetic Variant of Unknown Significance 
- c.4455G>T p.R1485S 0.25 Genetic Variant of Unknown Significance 
- c.5218G>A p.E1740K 0.50 Genetic Variant of Unknown Significance 
Exon 24 
- c.7116C>T p.I2172 0.25 Genetic Variant of Unknown Significance 
- c.8481C>T p.S2827 0.25 Genetic Variant of Unknown Significance 
Reported Variants 
Rare Variant 
Intron 3 - c.422+32C>G - 0 Genetic Variant of Unknown Significance 
Exon 20 - c.2815G>A p.G939S 1 Polymorphism 
Exon 23 - c.5178C>A p.N1726K 0 Causal Variant 
Polymorphisms (reported in dbSNP database) 
Intron 2 
rs56148603 c.273+10C>T - - Polymorphism 
rs10484326 c.274-31T>C - - Polymorphism 
Exon 7 rs17604693 c.913A>T p.I306F - Polymorphism 
Intron 9 rs2076296 c.1142-34C>T - - Polymorphism 
Intron 14 rs2076303 c.1904-49T>A - - Polymorphism 
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Exon 15 rs2076304 c.2091A>G p.G697 - Polymorphism 
Intron 16 rs7741957 c.2296+51T>C - - Polymorphism 
Exon 20 rs2064217 c.2862C>T p.C954 - Polymorphism 
Intron 20 rs2064218 c.2877+79C>A - - Polymorphism 
Intron 21 rs6942260 c.2985+70G>A - - Polymorphism 
Intron 22 rs6905839 c.3085-66G>A - - Polymorphism 
Exon 23 
rs28763966 c.4578C>A p.N1526K - Polymorphism 
rs6929069 c.5213G>A p.R1738Q - Polymorphism 
Exon 24 
rs2076300 c.7122C>T p.T2374 - Polymorphism 
rs2744380 c.8472G>C p.G2824 - Polymorphism 
3'UTR  rs12250 c.8616+197C>T - - Polymorphism 
 
3.1.3. Variants found in the ARVC and DCM cohorts 
The c.1534A>G and c.4022G>A novel variants discussed above (sections 3.1.1.1.3 and 3.1.1.1.4) 
were found in patients with ARVC and patients with DCM. The c.1534A>G variant was 
considered to be causative of ARVC, while the c.4022G>A variant was determined to be a 
Genetic Variant of Unknown Significance. In the DCM cohort, the c.1534A>G variant was found 
in one DCM proband, while the c.4022G>A variant was found in two DCM probands. We 
hypothesise that the c.1534A>G variant is causative of ARVC and DCM, using the criteria 
discussed in section 3.1.1.1.3. In the case of the c.4022G>A variant, we conclude that this 
variant is a Genetic Variant of Unknown Significance in the case of ARVC and DCM, using the 
criteria discussed in section 3.1.1.1.4. 
Figure 3.21 below indicates the positions of the variants (novel and reported) detected in the 
DSP gene in ARVC and DCM probands (that have not been reported in NCBI’s dbSNP database 
(http://www.ncbi.nlm.nih.gov/projects/SNP/)) in an attempt to provide a global overview of 




      
 












































































































































































































































































































































































































































































































3.2. MULTIPLEX LIGATION-DEPENDENT PROBE AMPLIFICATION (MLPA) 
In this study, the SALSA MLPA Kit P168 ARVC-PKP2 kit was used to screen the DSP gene for all 
ARVC samples.This kit is designed to detect deletions/duplications of one or more exons of the 
PKP2, DSP, JUP, TGFβ3 and RyR2 genes. MLPA can however also detect point mutations very 
close to the probe ligation site. Screening of the ARVC samples with MLPA revealed no 
deletions, insertions or copy number variations of the DSP gene (Figure 3.22).  The ratios 
approximating one in the Coffalyser output in Figure 3.21(B) indicate normal function and 
distribution of the DSP probes.  Based on the graphs it appears that DSP is largely intact.  






Figure 3.33: MLPA results: (A) MLPA electropherogram  and (B) Coffalyser output 





4. DISCUSSION AND CONCLUSIONS 
Genetic mutations in the DSP gene are known to cause ARVC. We hypothesised that 
mutations in the DSP gene may also cause familial and idiopathic DCM on the basis of 
overlap in phenotype between a syndromic form of DSP-associated disease (i.e., Carvajal 
syndrome) and DCM. We have found evidence to support this hypothesis as several 
individuals were classified as having causal mutations in the DSP gene:  2/62 (3%) of ARVC 
probands, 1/19 (5%) of index cases with familial DCM and 5/131 (4%) of apparently sporadic 
cases of idiopathic DCM. In the ARVC cohort, the variants classified as causal included the 
c.860A>G, c.1534A>G and c.8539A>C variants; in the DCM cohort, the variants classified as 
causal included the c.1222A>C, c.1228C>T, c.1534A>G, c.2288A>G, c.3085-2A>G, c.3260A>C 
and c.3806G>A variants. These data suggest that DSP mutations may be as important in 
ARVC as in DCM in South African patients. We also detected 22 known polymorphisms in 
the ARVC cohort and 23 polymorphisms (six novel, 17 reported) in the DCM cohort. 
We found a large number of Genetic Variants of Unknown Significance in this study, a 
finding that is similar to the experience of other investigators who have screened the 
desmosomal protein genes for mutations in ARVC (Fressart et al. 2010). In the ARVC cohort, 
these were the c.105G>A, c.1344G>A, c.4022G>A, c.8199G>C and c.8539A>C mutations, 
while in the DCM cohort, 12 variants were classified as being of unknown significance. 
Additional studies are required to determine their possible role in disease pathogenesis as 
previous studies have reported that a change in mRNA folding, and the consequent change 
in the stability of the mRNA, could lead to altered gene expression levels. mRNA with a 
more stable secondary structure could be harder for ribosome-associated helicases to 
unwind, thus limiting mRNA translation and reducing protein levels. On the other hand, 
more stable structures could cause mRNA persistence, which could potentially increase the 
rate of gene expression (Parmley and Hurst 2007). Changes in mRNA splicing could also lead 
to the production of alternative proteins, while changes in protein secondary structure 
could affect the function of the protein. These changes in the structure and/or function of 
the DSP protein could ultimately be causative of disease. If the Genetic Variants of Unknown 
Significance are shown to be pathogenic, the frequency of disease-causing mutations will 
increase to 10% in ARVC (6/62 probands), and 14% in sporadic DCM (21/150 probands); no 
Genetic Variants of Unknown Significance were found in patients with familial DCM. 
The incidence and prevalence of ARVC is uncertain and varies globally.  A literature scan 
revealed that approximately 39.2%-50% of symptomatic individuals with ARVC possess 
mutations in one of the genes encoding the desmosomal proteins (DSP, PKP2, JUP, DSC2 
and DSG2) (Corrado et al. 1998, Awad et al. 2008, den Haan et al. 2009,  Fowler et al. 2010, 
Fressart et al. 2010).  Based on the reports by den Haan, Marcus, Fressart and Fowler, the 
frequency of disease-causing mutations in DSP ranges from 1% to 20% (Marcus et al. 2007, 
den Haan et al 2009, Fowler et al. 2010, Fressart et al. 2010). The frequency of pathogenic 
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DSP mutations in our ARVC cohort of 3% is thus comparable to other populations in the 
world. 
We have screened the familial and idiopathic DCM cohorts for pathogenic DSP mutations 
and found causal variants in 5% of index cases with familial DCM and 4% of index cases with 
idiopathic DCM, and Genetic Variants of Unknown Significance in 9% of patients with 
idiopathic DCM. To the best of our knowledge, this is the first study of the prevalence of DSP 
mutations in familial and idiopathic DCM. Previous studies have identified DSP mutations in 
a syndromic form of dilated cardiomyopathy that is associated with woolly hair and striate 
palmoplantar keratoderma (Carvajal syndrome) (Norgett et al. 2000, Norgett et al. 2006, 
Uzumcu et al. 2006).  This is the first study in which a large number of potentially causal 
genetic mutations were discovered in African patients with familial or idiopathic DCM (Sliwa 
et al. 2005). This is also the first study to demonstrate that DSP is causative of non-
syndromic familial DCM, as is the case with the c.5178C>A variant, which was found to 
segregate with disease in a family with DCM. 
Another important finding of this study is the allelic heterogeneity demonstrated in DSP 
mutations. Two mutations in DSP were found to be causative of both ARVC and DCM. These 
include the c.1534A>G and c.4022G>A variants which were found in individuals with ARVC 
and individuals with idiopathic DCM.  The fact that the same mutations can lead to different 
types of cardiomyopathy suggests that ARVC and DCM could form part of a spectrum of 
heart disease that are caused by defects in desmosomal protein genes.  
STUDY LIMITATIONS 
One of the limitations of this study is that at the time of completion of this study, pedigree 
information was not available for the majority of the probands.  
Another limitation of this study is that the functional impact of the causal variants and the 
Genetic Variants of Unknown Significance was not established. Functional studies are 
required in order to determine the effects these mutations have on the function of the gene 
and to enable us to postulate the biological pathways by which these mutations could lead 
to disease.  
FUTURE WORK 
We intend to extend the pedigrees of the probands, with a view to determining whether the 
putative disease-causing mutations in the DSP gene segregate with disease. Furthermore, 
we intend to obtain blood samples for RNA extraction, and endomyocardial biopsy samples 
in affected individuals for studies of protein expression.  
The range of functional studies that we intend to perform on the Genetic Variants of 
Unknown Significance include analysis of mRNA of affected individuals to determine 
whether silent mutations are associated with cryptic splicing (Awad et al. 2006), analysis of 
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endomyocardial biopsy samples (where indicated on clinical grounds) for expression of 
desmoplakin, and a yeast-2-hybrid study of protein-protein interactions of mutant DSP 
protein. Other studies will include immunoblotting and confocal microscopy in human 
embryonic kidney 293 (HEK293) cell lines transfected to stably express either wild-type or 
mutant desmoplakin protein.  
CONLCUDING REMARKS 
We have found a number of disease-causing variants in the DSP gene in this study in 
individuals with ARVC, familial DCM and idiopathic DCM. Future work will focus on 
confirming the pathogenicity of these variants, as well as determining the functional effects 
of Genetic Variants of Unknown Significance. Characterisation of the functional effects of 
these variants would allow us to postulate the way in which these variants may lead to 
disease. It is also of interest that a number of mutations in DSP were deemed to be 
causative of ARVC and idiopathic DCM, which raises the possibility that ARVC and DCM 
could form part of a continuous spectrum of cardiomyopathy. 
Screening for the causal variants is now available in our laboratory to first degree relatives 
of affected individuals. Presymptomatic diagnosis by means of genetic screening would 
allow the early identification of individuals possessing disease-causing variants and who 
would then require extensive monitoring due to the age-related penetrance of the disease. 
Genetic screening would also allow the identification of individuals with concealed forms of 
the disease, and would allow risk stratification for preventative strategies such as the 
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1. Structure of the heart image:   Last Date accessed: 10 August 2010 
http://www.ohiohealth.com/bodymayo.cfm?id=6&action=thumbnail&image=/imag
es/image_popup/ch7_theheart.jpg&caption=A normal heart has two upper and two 
lower chambers. The upper chambers, the right and left atria, receive incoming 
blood. The lower chambers, the more muscular right and left ventricles, pump blood 
out of your heart. The heart valves, which keep blood flowing in the right direction, 
are gates at the chamber openings.  &title=Atrial septal defect (ASD) 







3. Arrhythmogenic right ventricular cardiomyopathy heart cross-section image: 
Last Date accessed: 10 August 2010 
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4. Dilated cardiomyopathy image: 
Last Date accessed: 10 August 2010 
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healthy heart, dilated cardiomyopathy causes the chambers of the heart to enlarge, 
which can lead to heart failure if left untreated.  &title=Dilated cardiomyopathy 
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APPENDIX 2   
SOLUTIONS 
Loading Buffer 
1 ml 5X GoTaq® Flexi Buffer (Promega) 
5 µl GelRed™ Nucleic Acid Gel Stain (Biotium)  
 
1X TBE Buffer 
10.8 g Tris (Promega) 
5.5 g Boric Acid (Riedel-de Haën) 
7.4 g EDTA (Promega) 
Make up to 1 litre with dH2O 
 
1.5% Agarose Gel 
1.5 g Agarose (Roche) 
Volume made up by 100 ml 1X TBE Buffer 
 
3% Agarose Gel 
3 g Agarose (Roche) 













100 bp DNA LADDER (PROMEGA) 
 
Image available from: 
http://www.promega.com/catalog/catalogproducts.aspx?categoryname=productleaf_179 
 
White bands represent DNA fragments of a known range of sizes, as indicated. This is run alongside 





MULTIPLEX LIGATION-DEPENDENT PROBE AMPLIFICATION (MLPA) PROBES 
MLPA was performed using the SALSA MLPA Kit P168 ARVC-PKP2. This kit contains 18 probes for 
PKP2, 7 probes for DSP and 3 probes each for JUP, TGFβ3 and RyR2. The probes in this kit are listed 





INTERPRETATION OF HIGH RESOLUTION MELT GRAPHS 
High resolution melt (HRM) analysis was used in this study for the screening of the ARVC and DCM 
cohorts for mutations. HRM runs were analysed by comparing the melting curves from HRM 
experiments of control samples to the melting curves of diseased samples from our cohort, and 
determining whether there was a difference in melting behaviour between the diseased and control 
sample amplicons. By reference to the melting curves plotted by the RotorGene 6000 software, it is 
possible to distinguish wildtype/control samples from mutation homozygotes and heterozygotes. In 
addition to this, the RotorGene software can be used to plot a derivative graph that indicates the 
rate of change of fluorescence over increasing temperature, which can be used in conjunction with 
the original melting curve to detect changes in amplicon melting behaviour.  
Figure 1 shows results from HRM experiments for DNA sequence variants identified in this study. 
Figure 1(A) shows the HRM curve for an amplicon with a single melting domain, indicating the 
wildtype and mutant samples, which are clearly distinguishable by their melting behaviour. Figure 
1(B) indicates the derivative graph of the HRM curve in Figure 1(A), which can be used in conjunction 
with the HRM curve to detect changes in amplicon melting behaviour. Figure 1(C) indicates the HRM 
curve for an amplicon with 2 melting domains, showing wildtype and mutant samples, while figure 
1(D) shows the derivative graph for this HRM curve. As shown, the 2 melting domains are clearly 
distinguishable with HRM. As shown in Figures 1(E) and (F), it is also possible to distinguish 3 melting 
domains in an amplicon by means of HRM. 
Figure 2(A) shows another melting curve of an amplicon with 2 melting domains, with a close-up 
view of the melting domain with inter-sample changes in Figure 2(B). As shown, wildtype samples 
can be distinguished from the heterozygote and homozygote mutant samples with the melt curve 
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